AptarGroup (ATR) 10-Q25 Oct 242024 Q3 Quarterly reportFinancial data

Company Profile

COVER

COVER - shares	9 Months Ended
COVER - shares	Sep. 30, 2024	Oct. 21, 2024
Cover [Abstract]
Document Type	10-Q
Document Quarterly Report	true
Document Period End Date	Sep. 30, 2024
Document Transition Report	false
Entity File Number	1-11846
Entity Registrant Name	AptarGroup, Inc
Entity Incorporation, State or Country Code	DE
Entity Tax Identification Number	36-3853103
Entity Address, Address Line One	265 EXCHANGE DRIVE
Entity Address, Address Line Two	SUITE 301
Entity Address, City or Town	CRYSTAL LAKE
Entity Address, State or Province	IL
Entity Address, Postal Zip Code	60014
City Area Code	815
Local Phone Number	477-0424
Title of 12(b) Security	Common Stock, $.01 par value
Trading Symbol	ATR
Security Exchange Name	NYSE
Entity Current Reporting Status	Yes
Entity Interactive Data Current	Yes
Entity Filer Category	Large Accelerated Filer
Entity Small Business	false
Entity Emerging Growth Company	false
Entity Shell Company	false
Entity Common Stock, Shares Outstanding		66,543,252
Current Fiscal Year End Date	--12-31
Document Fiscal Year Focus	2024
Document Fiscal Period Focus	Q3
Entity Central Index Key	0000896622
Amendment Flag	false

CONDENSED CONSOLIDATED STATEMEN

CONDENSED CONSOLIDATED STATEMENTS OF INCOME - USD ($) shares in Thousands, $ in Thousands	3 Months Ended		9 Months Ended
	Sep. 30, 2024	Sep. 30, 2023	Sep. 30, 2024	Sep. 30, 2023
Income Statement [Abstract]
Net Sales	$ 909,291	$ 892,997	$ 2,734,802	$ 2,648,970
Operating Expenses:
Cost of sales (exclusive of depreciation and amortization shown below)	558,511	566,691	1,708,707	1,697,824
Selling, research & development and administrative	141,604	138,137	443,714	427,488
Depreciation and amortization	67,015	62,686	196,332	184,212
Restructuring initiatives	3,864	6,161	9,659	19,628
Total Operating Expenses	770,994	773,675	2,358,412	2,329,152
Operating Income	138,297	119,322	376,390	319,818
Other (Expense) Income:
Interest expense	(12,290)	(9,984)	(32,526)	(29,900)
Interest income	3,022	946	9,022	2,266
Net investment gain (loss)	1,043	(1,240)	1,495	1,839
Equity in results of affiliates	(77)	1,002	(168)	1,514
Miscellaneous income (expense), net	1,136	3	(518)	(1,341)
Total Other Expense	(7,166)	(9,273)	(22,695)	(25,622)
Income before Income Taxes	131,131	110,049	353,695	294,196
Provision for Income Taxes	31,209	25,751	80,382	72,265
Net Income	99,922	84,298	273,313	221,931
Net Loss (Gain) Attributable to Noncontrolling Interests	117	(2)	284	201
Net Income Attributable to AptarGroup, Inc.	$ 100,039	$ 84,296	$ 273,597	$ 222,132
Net Income Attributable to AptarGroup, Inc. per Common Share:
Basic (in dollars per share)	$ 1.51	$ 1.28	$ 4.13	$ 3.39
Diluted (in dollars per share)	$ 1.48	$ 1.26	$ 4.05	$ 3.32
Average Number of Shares Outstanding:
Basic (in shares)	66,445	65,707	66,274	65,550
Diluted (in shares)	67,716	67,035	67,574	66,865
Dividends per Common Share (in dollars per share)	$ 0.45	$ 0.41	$ 1.27	$ 1.17

CONDENSED CONSOLIDATED STATEM_2

CONDENSED CONSOLIDATED STATEMENTS OF COMPREHENSIVE INCOME - USD ($) $ in Thousands	3 Months Ended		9 Months Ended
	Sep. 30, 2024	Sep. 30, 2023	Sep. 30, 2024	Sep. 30, 2023
Statement of Comprehensive Income [Abstract]
Net Income	$ 99,922	$ 84,298	$ 273,313	$ 221,931
Other Comprehensive Income (Loss):
Foreign currency translation adjustments	66,736	(52,514)	625	(28,639)
Changes in derivative (losses) gains, net of tax	(5,711)	2,707	(202)	(2,424)
Defined benefit pension plan, net of tax
Actuarial (loss) gain, net of tax	(634)	(5)	(532)	63
Amortization of prior service cost included in net income, net of tax	22	33	62	98
Amortization of net loss included in net income, net of tax	214	161	578	483
Total defined benefit pension plan, net of tax	(398)	189	108	644
Total other comprehensive income (loss)	60,627	(49,618)	531	(30,419)
Comprehensive Income	160,549	34,680	273,844	191,512
Comprehensive (Income) Loss Attributable to Noncontrolling Interests	(866)	88	(158)	319
Comprehensive Income Attributable to AptarGroup, Inc.	$ 159,683	$ 34,768	$ 273,686	$ 191,831

CONDENSED CONSOLIDATED BALANCE

CONDENSED CONSOLIDATED BALANCE SHEETS - USD ($) $ in Thousands	Sep. 30, 2024	Dec. 31, 2023
Assets
Cash and equivalents	$ 325,524	$ 223,643
Short-term investments	2,387	0
Accounts and notes receivable, less current expected credit loss (“CECL”) of $14,264 in 2024 and $16,217 in 2023	698,989	677,822
Inventories	488,540	513,053
Prepaid and other	150,164	134,761
Total Current Assets	1,665,604	1,549,279
Land	29,924	30,090
Buildings and improvements	776,798	748,897
Machinery and equipment	3,270,657	3,183,097
Property, Plant and Equipment, Gross	4,077,379	3,962,084
Less: Accumulated depreciation	(2,572,170)	(2,484,021)
Property, Plant and Equipment, Net	1,505,209	1,478,063
Investments in equity securities	51,052	49,203
Goodwill	968,293	963,418
Intangible assets, net	271,215	283,211
Operating lease right-of-use assets	75,416	59,074
Miscellaneous	88,426	69,642
Total Other Assets	1,454,402	1,424,548
Total Assets	4,625,215	4,451,890
Current Liabilities:
Revolving credit facility and overdrafts	222,817	81,794
Current maturities of long-term obligations, net of unamortized debt issuance costs	30,295	376,426
Accounts payable, accrued and other liabilities	773,540	793,089
Total Current Liabilities	1,026,652	1,251,309
Long-Term Obligations, net of unamortized debt issuance costs	822,731	681,188
Deferred income taxes	13,896	19,016
Retirement and deferred compensation plans	71,853	62,795
Operating lease liabilities	58,864	45,267
Deferred and other non-current liabilities	77,578	71,017
Commitments and contingencies	0	0
Total Deferred Liabilities and Other	222,191	198,095
AptarGroup, Inc. stockholders’ equity
Common stock, $.01 par value, 199 million shares authorized, 72.3 million and 71.7 million shares issued as of September 30, 2024 and December 31, 2023, respectively	723	717
Capital in excess of par value	1,107,597	1,044,429
Retained earnings	2,299,540	2,109,816
Accumulated other comprehensive loss	(308,880)	(308,734)
Less: Treasury stock at cost, 5.8 million and 5.8 million shares as of September 30, 2024 and December 31, 2023	(559,971)	(539,404)
Total AptarGroup, Inc. Stockholders’ Equity	2,539,009	2,306,824
Noncontrolling interests in subsidiaries	14,632	14,474
Total Stockholders’ Equity	2,553,641	2,321,298
Total Liabilities and Stockholders’ Equity	$ 4,625,215	$ 4,451,890

CONDENSED CONSOLIDATED BALANC_2

CONDENSED CONSOLIDATED BALANCE SHEETS (Parenthetical) - USD ($) $ in Thousands, shares in Millions	Sep. 30, 2024	Dec. 31, 2023
Statement of Financial Position [Abstract]
Accounts and notes receivable, allowance for credit loss	$ 14,264	$ 16,217
Common stock, par value (in dollars per share)	$ 0.01	$ 0.01
Common stock, shares authorized (in shares)	199	199
Common stock, shares issued (in shares)	72.3	71.7
Treasury stock (in shares)	5.8	5.8

CONDENSED CONSOLIDATED STATEM_3

CONDENSED CONSOLIDATED STATEMENTS OF CHANGES IN EQUITY - USD ($) $ in Thousands	Total	Retained Earnings	Accumulated Other Comprehensive (Loss) Income	Common Stock Par Value	Treasury Stock	Capital in Excess of Par Value	Non- Controlling Interest
Beginning balance at Dec. 31, 2022	$ 2,068,204	$ 1,929,240	$ (341,366)	$ 709	$ (503,266)	$ 968,618	$ 14,269
Increase (Decrease) in Stockholders' Equity
Net income (loss)	221,931	222,132					(201)
Foreign currency translation adjustments	(28,639)	(227)	(28,294)				(118)
Changes in unrecognized pension gains (losses) and related amortization, net of tax	644		644
Changes in derivative losses, net of tax	(2,424)		(2,424)
Stock awards and option exercises	67,986			6	7,935	60,045
Cash dividends declared on common stock	(76,711)	(76,711)
Treasury stock purchased	(37,302)				(37,302)
Ending balance at Sep. 30, 2023	2,213,689	2,074,434	(371,440)	715	(532,633)	1,028,663	13,950
Beginning balance at Jun. 30, 2023	2,188,426	2,017,065	(321,913)	713	(526,484)	1,005,007	14,038
Increase (Decrease) in Stockholders' Equity
Net income (loss)	84,298	84,296					2
Foreign currency translation adjustments	(52,514)	(1)	(52,423)				(90)
Changes in unrecognized pension gains (losses) and related amortization, net of tax	189		189
Changes in derivative losses, net of tax	2,707		2,707
Stock awards and option exercises	25,772			2	2,114	23,656
Cash dividends declared on common stock	(26,926)	(26,926)
Treasury stock purchased	(8,263)				(8,263)
Ending balance at Sep. 30, 2023	2,213,689	2,074,434	(371,440)	715	(532,633)	1,028,663	13,950
Beginning balance at Dec. 31, 2023	2,321,298	2,109,816	(308,734)	717	(539,404)	1,044,429	14,474
Increase (Decrease) in Stockholders' Equity
Net income (loss)	273,313	273,597					(284)
Foreign currency translation adjustments	625	235	(52)				442
Changes in unrecognized pension gains (losses) and related amortization, net of tax	108		108
Changes in derivative losses, net of tax	(202)		(202)
Stock awards and option exercises	73,910			6	10,736	63,168
Cash dividends declared on common stock	(84,108)	(84,108)
Treasury stock purchased	(31,303)				(31,303)
Ending balance at Sep. 30, 2024	2,553,641	2,299,540	(308,880)	723	(559,971)	1,107,597	14,632
Beginning balance at Jun. 30, 2024	2,410,215	2,229,377	(368,524)	721	(547,685)	1,082,560	13,766
Increase (Decrease) in Stockholders' Equity
Net income (loss)	99,922	100,039					(117)
Foreign currency translation adjustments	66,736	0	65,753				983
Changes in unrecognized pension gains (losses) and related amortization, net of tax	(398)		(398)
Changes in derivative losses, net of tax	(5,711)		(5,711)
Stock awards and option exercises	26,922			2	1,883	25,037
Cash dividends declared on common stock	(29,876)	(29,876)
Treasury stock purchased	(14,169)				(14,169)
Ending balance at Sep. 30, 2024	$ 2,553,641	$ 2,299,540	$ (308,880)	$ 723	$ (559,971)	$ 1,107,597	$ 14,632

CONDENSED CONSOLIDATED STATEM_4

CONDENSED CONSOLIDATED STATEMENTS OF CASH FLOWS - USD ($) $ in Thousands	3 Months Ended		9 Months Ended		12 Months Ended
	Sep. 30, 2024	Sep. 30, 2023	Sep. 30, 2024	Sep. 30, 2023	Dec. 31, 2023
Cash Flows from Operating Activities:
Net Income	$ 99,922	$ 84,298	$ 273,313	$ 221,931
Adjustments to reconcile net income to net cash provided by operations:
Depreciation			162,925	150,718
Amortization			33,407	33,494
Stock-based compensation			37,962	36,084
(Release) provision for CECL			(1,221)	3,449
Gain on disposition of fixed assets			(462)	(3,753)
Net gain on remeasurement of equity securities			(1,495)	(1,839)
Deferred income taxes			(11,653)	(16,978)
Defined benefit plan expense			9,296	10,659
Equity in results of affiliates			168	(1,514)
Changes in balance sheet items, excluding effects from foreign currency adjustments:
Accounts and other receivables			(24,054)	(43,061)
Inventories			22,653	(5,188)
Prepaid and other current assets			(13,970)	(19,236)
Accounts payable, accrued and other liabilities			(14,371)	3,860
Income taxes payable			6,672	(8,732)
Retirement and deferred compensation plan liabilities			(3,832)	1,323
Other changes, net			(10,164)	(5,615)
Net Cash Provided by Operations			465,174	355,602
Cash Flows from Investing Activities:
Capital expenditures			(210,416)	(231,199)
Proceeds from sale of property, plant and equipment			1,020	6,037
Maturity of short-term investment			(2,242)	0
Acquisition of businesses, net of cash acquired and release of escrow			0	(16,570)
Acquisition of intangible assets, net			(13,242)	(3,648)
Proceeds from sale of investment in equity securities			0	5,604
Notes receivable, net			(776)	439
Net Cash Used by Investing Activities			(225,656)	(239,337)
Cash Flows from Financing Activities:
Proceeds from notes payable and overdrafts			22,302	24,392
Repayments of notes payable and overdrafts			(23,184)	(27,863)
Proceeds and (repayments) of short-term revolving credit facility, net			138,058	123,514
Proceeds from long-term obligations			168,614	257
Repayments of long-term obligations			(372,393)	(117,289)
Payment of contingent consideration obligation			0	(22,750)
Dividends paid			(84,108)	(76,711)
Proceeds from stock option exercises			44,364	39,742
Purchase of treasury stock			(31,303)	(37,302)
Net Cash Used by Financing Activities			(137,650)	(94,010)
Effect of Exchange Rate Changes on Cash			13	(12,914)
Net Increase in Cash and Equivalents and Restricted Cash			101,881	9,341
Cash and Equivalents and Restricted Cash at Beginning of Period			223,643	142,732	$ 142,732
Cash and Equivalents and Restricted Cash at End of Period	325,524	152,073	325,524	152,073	223,643
Cash and equivalents	325,524	151,573	325,524	151,573	223,643
Restricted cash included in prepaid and other	0	500	0	500
Total Cash and Equivalents and Restricted Cash shown in the Statement of Cash Flows	$ 325,524	$ 152,073	$ 325,524	$ 152,073	$ 223,643

SUMMARY OF SIGNIFICANT ACCOUNTI

SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES	9 Months Ended
SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES	Sep. 30, 2024
Accounting Policies [Abstract]
SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES	SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES BASIS OF PRESENTATION The accompanying unaudited Condensed Consolidated Financial Statements include the accounts of AptarGroup, Inc. and our subsidiaries. The terms “AptarGroup,” “Aptar,” “Company,” “we,” “us” or “our” as used herein refer to AptarGroup, Inc. and our subsidiaries. All significant intercompany accounts and transactions have been eliminated. Certain previously reported amounts have been reclassified to conform to the current period presentation. In the opinion of management, the unaudited Condensed Consolidated Financial Statements (the “Condensed Consolidated Financial Statements”) include all normal recurring adjustments necessary for a fair statement of consolidated financial position, results of operations, comprehensive income, changes in equity and cash flows for the interim periods presented. The accompanying Condensed Consolidated Financial Statements have been prepared by the Company, pursuant to the rules and regulations of the Securities and Exchange Commission (“SEC”). Certain information and footnote disclosures normally included in financial statements prepared in accordance with accounting principles generally accepted in the United States of America (“U.S. GAAP”) have been condensed or omitted pursuant to such rules and regulations, although we believe that the disclosures made are adequate to make the information presented not misleading. Also, certain financial position data included herein was derived from the audited Consolidated Financial Statements included in our Annual Report on Form 10-K for the year ended December 31, 2023 but does not include all disclosures required by U.S. GAAP. Accordingly, these Condensed Consolidated Financial Statements and related notes should be read in conjunction with the audited Consolidated Financial Statements and notes thereto included in our Annual Report on Form 10-K for the year ended December 31, 2023. The results of operations of any interim period are not necessarily indicative of the results that may be expected for the year. ADOPTION OF RECENT ACCOUNTING STANDARDS Changes to U.S. GAAP are established by the Financial Accounting Standards Board (“FASB”) in the form of Accounting Standards Updates (“ASUs”) to the FASB’s Accounting Standards Codification. In March 2020, the FASB issued ASU 2020-04, which provides optional expedients and exceptions for applying U.S. GAAP to contracts, hedging relationships and other transactions affected by reference rate reform if certain criteria are met. The amendments to this update apply only to contracts, hedging relationships and other transactions that reference LIBOR or another reference rate expected to be discontinued because of reference rate reform. ASU 2020-04 was further amended in January 2021 by ASU 2021-01 which clarified the applicability of certain provisions. Both standards are effective upon issuance and could be adopted any time prior to December 31, 2022. The guidance in ASU 2020-04 and ASU 2021-01 is optional and may be elected over time as reference rate reform activities occur. We adopted this guidance in the second quarter of 2023 and have transitioned away from the London Interbank Offered Rate (“LIBOR”) to the Secured Overnight Financing Rate (“SOFR”) in our revolving credit facility. In November 2023, the FASB issued ASU 2023-07, Improvement to Reportable Segment Disclosures, which requires enhanced disclosures about significant segment expenses on an annual and interim basis. The amendments in ASU 2023-07 are effective for fiscal years beginning after December 15, 2023 and interim periods within fiscal years beginning after December 15, 2024, with early adoption permitted, and are to be applied on a retrospective basis. We are evaluating the impact of the standard on our segment reporting disclosures. In December 2023, the FASB issued ASU 2023-09, Improvements to Income Tax Disclosures, which is intended to improve income tax disclosure requirements by requiring (i) consistent categories and greater disaggregation of information in the rate reconciliation and (ii) the disaggregation of income taxes paid by jurisdiction. The guidance makes several other changes to income tax disclosure requirements. The amendments in ASU 2023-09 are effective for fiscal years beginning after December 15, 2024, with early adoption permitted, and are required to be applied prospectively with the option of retrospective application. We are evaluating the impact of the standard on our income tax disclosures. Other accounting standards that have been issued by the FASB or other standards-setting bodies did not have a material impact on our Condensed Consolidated Financial Statements. INCOME TAXES We compute taxes on income in accordance with the tax rules and regulations of the many taxing authorities where income is earned. The income tax rates imposed by these taxing authorities may vary substantially. Taxable income may differ from pre-tax income for U.S. GAAP financial accounting purposes. To the extent that these differences create temporary differences between the tax basis of an asset or liability and our reported amount in the U.S. GAAP financial statements, an appropriate provision for deferred income taxes is made. We maintain our assertion that the cash and distributable reserves at our non-U.S. affiliates are indefinitely reinvested with the following exceptions: all earnings in Germany and the pre-2020 earnings in Italy, Switzerland and Colombia. As of September 30, 2024, under currently enacted laws, we do not have a balance of foreign earnings that will be subject to U.S. taxation upon repatriation. We will provide for the necessary withholding and local income taxes when management decides that an affiliate should make a distribution. These decisions are made taking into consideration the financial requirements of the non-U.S. affiliates and our global cash management goals. See Note 5 – Income Taxes for more information. We provide a liability for the amount of unrecognized tax benefits from uncertain tax positions. This liability is provided whenever we determine that a tax benefit will not meet a more-likely-than-not threshold for recognition. We are subject to the examination of our returns and other tax matters by the U.S. Internal Revenue Service as well as other tax authorities and governmental bodies. We believe that we have adequately provided a tax reserve for any adjustments that may result from tax examinations or uncertain tax positions. However, the outcome of tax audits cannot be predicted with certainty. If any issues addressed in our tax audits are resolved in a manner inconsistent with its expectations, we could be required to adjust its provision for income taxes in the period such resolution occurs. The resolution of each of these audits is not expected to be material to our Condensed Consolidated Financial Statements. ASSETS HELD FOR SALE Assets to be disposed of by sale are reported at the lower of their carrying amount or fair value less costs to sell, and are not depreciated while they are held for sale. During the second quarter of 2023, we recorded $0.7 million as assets held for sale within prepaid and other on our Condensed Consolidated Balance Sheets related to three buildings located in France. During the third quarter of 2023, two of the three buildings were sold and we recognized a $0.8 million gain on sale. As of September 30, 2024, one building is still held for sale and expected to be sold during 2025. SUPPLY CHAIN FINANCE PROGRAM We facilitate a supply chain finance program (“SCF”) across Europe and the U.S. that is administered by a third-party platform. Eligible suppliers can elect to receive early payment of invoices, less an interest deduction, and negotiate their receivable sales arrangements through the third-party platform on behalf of the respective SCF bank. We are not a party to those agreements, and the terms of our payment obligations are not impacted by a supplier's participation in the SCF. Accordingly, we have concluded that this program continues to be a trade payable program and is not indicative of a borrowing arrangement. Under these agreements, the average payment terms range from 60 to 120 days and are based on industry standards and best practices within each of our regions. All outstanding amounts related to suppliers participating in the SCF are recorded within accounts payable, accrued and other liabilities in our Condensed Consolidated Balance Sheets, and associated payments are included in operating activities within our Condensed Consolidated Statements of Cash Flows. As of September 30, 2024, the amounts due to suppliers participating in the SCF and included in accounts payable, accrued and other liabilities were approximately $35.0 million. Collection and payment periods tend to be longer for our operations located outside the United States due to local business practices. We have also seen an increasing trend in pressure from certain customers to lengthen their payment terms. As the majority of our products are made to order, we have not needed to keep significant amounts of finished goods inventory to meet customer requirements. However, some of our contracts specify an amount of finished goods safety stock we are required to maintain. To the extent our financial position allows and there is a clear financial benefit, we from time-to-time benefit from early payment discounts with some suppliers. We have lengthened the payment terms with our suppliers to be in line with customer trends. While we have offered a third party alternative for our suppliers to receive payments sooner, we generally do not utilize these offerings from our customers as the economic conditions currently are not beneficial for us.

REVENUE

REVENUE	9 Months Ended
REVENUE	Sep. 30, 2024
Revenue from Contract with Customer [Abstract]
REVENUE	REVENUE In prior years, our geographic revenue disclosure was based on shipped from location. Beginning in 2024, we have started to report our geographic sales based on shipped to locations to give the reader a better understanding of the geographies we serve. Revenue by segment and geography based on shipped to locations for the three and nine months ended September 30, 2024 and 2023 were as follows: For the Three Months Ended September 30, 2024 Segment Europe Domestic Latin Asia Total Aptar Pharma $ 204,835 $ 142,747 $ 10,925 $ 62,087 $ 420,594 Aptar Beauty 182,708 59,954 37,565 22,632 302,859 Aptar Closures 57,586 88,870 20,665 18,717 185,838 Total $ 445,129 $ 291,571 $ 69,155 $ 103,436 $ 909,291 For the Three Months Ended September 30, 2023 Segment Europe Domestic Latin Asia Total Aptar Pharma $ 198,546 $ 125,730 $ 13,549 $ 51,363 $ 389,188 Aptar Beauty 201,127 55,674 42,497 24,682 323,980 Aptar Closures 55,508 85,612 21,863 16,846 179,829 Total $ 455,181 $ 267,016 $ 77,909 $ 92,891 $ 892,997 For the Nine Months Ended September 30, 2024 Segment Europe Domestic Latin Asia Total Aptar Pharma $ 624,503 $ 407,291 $ 36,848 $ 173,778 $ 1,242,420 Aptar Beauty 579,638 189,849 117,959 64,220 951,666 Aptar Closures 165,507 262,154 64,221 48,834 540,716 Total $ 1,369,648 $ 859,294 $ 219,028 $ 286,832 $ 2,734,802 For the Nine Months Ended September 30, 2023 Segment Europe Domestic Latin Asia Total Aptar Pharma $ 598,728 $ 354,655 $ 37,415 $ 145,136 $ 1,135,934 Aptar Beauty 622,253 171,602 118,563 67,538 979,956 Aptar Closures 171,645 251,780 63,108 46,547 533,080 Total $ 1,392,626 $ 778,037 $ 219,086 $ 259,221 $ 2,648,970 We perform our obligations under a contract with a customer by transferring goods and/or services in exchange for consideration from the customer. The timing of performance will sometimes differ from the timing of the invoicing for the associated consideration from the customer, thus resulting in the recognition of a contract asset or a contract liability. We recognize a contract asset when we transfer control of goods or services to a customer prior to invoicing for the related performance obligation. The contract asset is transferred to accounts receivable when the product is shipped and invoiced to the customer. We recognize a contract liability if the customer's payment of consideration precedes the entity's performance. The opening and closing balances of our contract asset and contract liabilities were as follows: Balance as of December 31, 2023 Balance as of September 30, 2024 Increase/ Contract asset (current) $ 18,033 $ 15,000 $ (3,033) Contract liability (current) 60,507 64,904 4,397 Contract liability (long-term) 37,756 43,235 5,479 The differences in the opening and closing balances of our contract asset and contract liabilities are primarily the result of timing differences between our performance and the invoicing. The total amount of revenue recognized during the current year against contract liabilities is $76.5 million, including $40.2 million relating to contract liabilities at the beginning of the year. Current contract assets are included within Prepaid and other, while current contract liabilities and long-term contract liabilities are included within Accounts payable, accrued and other liabilities and Deferred and other non-current liabilities, respectively, within our Condensed Consolidated Balance Sheets. Determining the Transaction Price In most cases, the transaction price for each performance obligation is stated in the contract. In determining the variable amounts of consideration within the transaction price (such as volume-based customer rebates), we include an estimate of the expected amount of consideration as revenue. We apply the expected value method based on all of the information (historical, current, and forecast) that is reasonably available and identify reasonable estimates based on this information. We apply the method consistently throughout the contract when estimating the effect of an uncertainty on the amount of variable consideration to which we will be entitled. Product Sales We primarily manufacture and sell drug and consumer product dosing, dispensing and protection technologies. The amount of consideration is typically fixed for customers. At the time of delivery, the customer is invoiced at the agreed-upon price. Revenue from product sales is typically recognized upon manufacture or shipment, when control of the goods transfers to the customer. To determine when the control transfers, we typically assess, among other things, the shipping terms of the contract, shipping being one of the indicators of transfer of control. For a majority of product sales, control of the goods transfers to the customer at the time of shipment of the goods. Once the goods are shipped, we are precluded from redirecting the shipment to another customer. Therefore, our performance obligation is satisfied at the time of shipment. For sales in which control transfers upon delivery, shipping and/or handling costs that occur before the customer obtains control of the goods are deemed to be fulfillment activities and are accounted for as fulfillment costs and revenue is recorded upon final delivery to the customer location. We have elected to account for shipping and handling costs that occur after the customer has obtained control of a good as fulfillment costs rather than as a promised service. We do not have any material significant payment terms as payment is typically received shortly after the point of sale. There also exist instances where we manufacture highly customized products that have no alternative use to us and for which we have an enforceable right to payment for performance completed to date. For these products, we transfer control and recognize revenue over time by measuring progress towards completion using the output method based on the number of products produced. As we normally make our products to a customer’s order, the time between production and shipment of our products is typically within a few weeks. We believe this measurement provides a faithful depiction of the transfer of goods as the costs incurred reflect the value of the products produced. As a part of our customary business practice, we offer a standard warranty that the products will materially comply with the technical specifications and will be free from material defects. Because such warranties are not sold separately, do not provide for any service beyond a guarantee of a product’s initial specifications, and are not required by law, there is no revenue deferral for these types of warranties. Tooling Sales We also build or contract for molds and other tools (collectively defined as “tooling”) necessary to produce our products. As with product sales, we recognize revenue when control of the tool transfers to the customer. If the tooling is highly customized with no alternative use to us and we have an enforceable right to payment for performance completed to date, we transfer control and recognize revenue over time by measuring progress towards completion using the input method based on costs incurred relative to total estimated costs to completion. Otherwise, revenue for the tooling is recognized at the point in time when the customer approves the tool. We do not have any significant payment terms as payment is typically either received during the mold-build process or shortly after completion. In certain instances, we offer extended warranties on our tools above and beyond the normal standard warranties. We normally receive payment at the inception of the contract and recognize revenue over the term of the contract. We do not have any material extended warranties as of September 30, 2024 or December 31, 2023. Service Sales We also provide services to our customers. As with product sales, we recognize revenue based on completion of each performance obligation of the service contract. Milestone deliverables and upfront payments are tied to specific performance obligations and recognized upon satisfaction of the individual performance obligation. Royalty Revenue We determine the amount and timing of royalty revenue based on our contractual agreements with customers. We recognize royalty revenue when earned under the terms of the agreements and when we consider realization of payment to be probable. Contract Costs We do not incur significant costs to obtain or fulfill revenue contracts. Credit Risk We are exposed to credit losses primarily through our product sales, tooling sales and services to our customers. We assess each customer’s ability to pay for the products we sell by conducting a credit review. The credit review considers our expected billing exposure and timing for payment and the customer’s established credit rating, or our assessment of the customer’s creditworthiness based on our analysis of their financial statements when a credit rating is not available. We also consider contract terms and conditions, country and political risks, and business strategy in our evaluation. A credit limit is established for each customer based on the outcome of this review. We monitor our ongoing credit exposure through active review of customer balances against contract terms and due dates. Our activities include timely account reconciliation, dispute resolution and payment confirmation. We may employ collection agencies and legal counsel to pursue recovery of defaulted receivables.

INVENTORIES

INVENTORIES	9 Months Ended
INVENTORIES	Sep. 30, 2024
Inventory Disclosure [Abstract]
INVENTORIES	INVENTORIES Inventories, by component net of reserves, consisted of: September 30, December 31, Raw materials $ 140,194 $ 145,798 Work in process 179,857 176,191 Finished goods 168,489 191,064 Total $ 488,540 $ 513,053

GOODWILL AND OTHER INTANGIBLE A

GOODWILL AND OTHER INTANGIBLE ASSETS	9 Months Ended
GOODWILL AND OTHER INTANGIBLE ASSETS	Sep. 30, 2024
Goodwill and Intangible Assets Disclosure [Abstract]
GOODWILL AND OTHER INTANGIBLE ASSETS	GOODWILL AND OTHER INTANGIBLE ASSETS The changes in the carrying amount of goodwill for the nine months ended September 30, 2024 by reporting segment were as follows: Aptar Aptar Aptar Closures Total Balance as of December 31, 2023 $ 508,447 $ 287,097 $ 167,874 $ 963,418 Foreign currency exchange effects 4,062 986 (173) 4,875 Balance as of September 30, 2024 $ 512,509 $ 288,083 $ 167,701 $ 968,293 The table below shows a summary of intangible assets as of September 30, 2024 and December 31, 2023. September 30, 2024 December 31, 2023 Weighted Average Amortization Period (Years) Gross Accumulated Net Gross Accumulated Net Amortized intangible assets: Patents 12.4 $ 18,862 $ (2,219) $ 16,643 $ 7,362 $ (1,754) $ 5,608 Acquired technology 11.3 143,652 (80,584) 63,068 142,837 (70,520) 72,317 Customer relationships 13.6 310,205 (143,613) 166,592 308,889 (124,648) 184,241 Trademarks and trade names 7.9 44,187 (36,717) 7,470 43,932 (33,368) 10,564 License agreements and other 20.3 26,471 (9,029) 17,442 17,213 (6,732) 10,481 Total intangible assets 13.3 $ 543,377 $ (272,162) $ 271,215 $ 520,233 $ (237,022) $ 283,211 Aggregate amortization expense for the intangible assets above for the quarters ended September 30, 2024 and 2023 was $11,733 and $11,400, respectively. Aggregate amortization expense for the intangible assets above for the nine months ended September 30, 2024 and 2023 was $33,407 and $33,494, respectively. As of September 30, 2024, future estimated amortization expense for the years ending December 31 is as follows: 2024 $ 11,067 (remaining estimated amortization for 2024) 2025 43,616 2026 41,540 2027 33,354 2028 29,203 Thereafter 112,435 Future amortization expense may fluctuate depending on changes in foreign currency rates. The estimates for amortization expense noted above are based upon foreign exchange rates as of September 30, 2024.

INCOME TAXES

INCOME TAXES	9 Months Ended
INCOME TAXES	Sep. 30, 2024
Income Tax Disclosure [Abstract]
INCOME TAXES	INCOME TAXES The tax provision for interim periods is determined using the estimated annual effective consolidated tax rate, based on the current estimate of full-year earnings and related estimated full year-taxes, adjusted for the impact of discrete quarterly items. The Organization for Economic Co-operation and Development released Model Global Anti-Base Erosion rules under Pillar Two. Certain countries in which we operate have enacted laws implementing aspects of Pillar Two beginning in 2024. These enacted laws relate to the Pillar Two Income Inclusion Rule and Qualified Domestic Minimum Top-Up Tax with an effective date in 2024. We have analyzed the provisions in the applicable jurisdictions and provided for the appropriate tax amounts. We do not expect a material impact from the implementation of these rules for 2024 but we will continue to monitor future legislations for additional guidance. The effective tax rate for the three months ended September 30, 2024 and 2023, respectively, was 23.8% and 23.4%. The effective tax rate for the three months ended September 30, 2024 was slightly higher than the same period of 2023 primarily due to an unfavorable mix of earnings forecasted in the second half of 2024. The effective tax rate for the nine months ended September 30, 2024 and 2023, respectively, was 22.7% and 24.6%. On a nine-month basis, the effective tax rate was lower than the same period of 2023 primarily due to increased tax benefits from share-based compensation and tax incentives in certain non-U.S. jurisdictions for intellectual property development activities.

DEBT

DEBT	9 Months Ended
DEBT	Sep. 30, 2024
Debt Disclosure [Abstract]
DEBT	DEBT Revolving Credit Facility and Overdrafts At September 30, 2024 and December 31, 2023, our revolving credit facility and overdrafts consisted of the following: September 30, December 31, Revolving credit facility $ 222,650 $ 80,662 Overdraft 167 1,132 $ 222,817 $ 81,794 Aptar has a revolving credit facility (the “revolving credit facility”) with a syndicate of banks that provides us with unsecured financing of up to $600 million, which may be increased by up to $300 million more, subject to the satisfaction of certain conditions. The revolving credit facility is available in the U.S. and to our wholly-owned UK subsidiary and could be drawn in various currencies including USD, EUR, GBP, and CHF. The revolving credit facility was set to mature in June 2026, but on July 2, 2024, Aptar entered into a new amended and restated agreement (the “amended revolving credit facility”) that extended the maturity date to July 2029, subject to a maximum of two one-year extensions in certain circumstances, As of December 31, 2023, Aptar had utilized $36.5 million and €40.0 million ($44.2 million) under the revolving credit facility in the U.S. and no balance was utilized by our wholly-owned UK subsidiary. As of September 30, 2024, Aptar had utilized €200 million ($222.7 million) under the amended revolving credit facility in the U.S. and no balance was utilized by our wholly-owned UK subsidiary. On July 2, 2024, we entered into a term loan with a syndicate of banks (the “Term Loan”). The Term Loan matures in July 2027 and enabled drawings on the loan until September 30, 2024 and provided for unsecured financing of up to $330 million available in the U.S. Funds are to be used to refinance near-term maturities and for general corporate purposes. As of September 30, 2024, $166 million was utilized under the Term Loan facility and the unused portion expired. There are no compensating balance requirements associated with our amended revolving credit facility. Each borrowing under the amended revolving credit facility will bear interest at rates based on SOFR (in the case of USD), EURIBOR (in the case of EUR), SONIA (in the case of GBP), SARON (in the case of CHF), prime rates or other similar rates, in each case plus an applicable margin. The amended revolving credit facility also provides mechanics relating to a transition away from designated benchmark rates for other available currencies and the replacement of any such applicable benchmark by a replacement alternative benchmark rate or mechanism for loans made in the applicable currency. A facility fee on the total amount of the amended revolving credit facility is also payable quarterly, regardless of usage. The applicable margins for borrowings under the amended revolving credit facility and the facility fee percentage may change from time to time depending on changes in our consolidated leverage ratio. Aptar has an unsecured money market borrowing arrangement to provide short-term financing of up to $30 million that is available in the U.S. No borrowing on this facility is permitted over a quarter end date. As such, no balance was utilized under this arrangement as of September 30, 2024 or December 31, 2023. Long-Term Obligations On February 26, 2024, we repaid in full the $100 million 3.49% Senior Unsecured Notes that were due in February 2024. On July 19, 2024, we repaid in full the €200 million 1.17% Senior Unsecured Notes that were due in July 2024. On September 5, 2024, we repaid in full the $50 million 3.4% Senior Unsecured Notes that were due in September 2024. These were repaid using borrowings from our revolving credit facility or the Term Loan. At September 30, 2024 and December 31, 2023, our long-term obligations consisted of the following: September 30, 2024 December 31, 2023 Notes payable 0.10% – 2.25%, due in monthly and annual installments through 2031 $ 16,893 $ 14,988 Senior unsecured notes 3.4%, due in 2024 — 50,000 Senior unsecured notes 3.5%, due in 2024 — 100,000 Senior unsecured notes 1.2%, due in 2024 — 220,810 Senior unsecured notes 3.6%, due in 2025 125,000 125,000 Senior unsecured notes 3.6%, due in 2026 125,000 125,000 Term loan 6.4% floating, due in 2027 166,000 — Senior unsecured notes 3.6%, due in 2032, net of discount of $0.8 million 399,232 399,154 Finance Lease Liabilities 24,917 26,478 Unamortized debt issuance costs (4,016) (3,816) $ 853,026 $ 1,057,614 Current maturities of long-term obligations (30,295) (376,426) Total long-term obligations $ 822,731 $ 681,188 The aggregate long-term maturities, excluding finance lease liabilities and unamortized debt issuance costs, which are discussed in Note 7, due annually from the current balance sheet date for the next five years and thereafter are: Year One $ 26,912 Year Two 134,438 Year Three 271,276 Year Four 111 Year Five 78 Thereafter 399,310 Covenants Our amended revolving credit facility and corporate long-term obligations require us to satisfy certain financial and other covenants including: Requirement Level at September 30, 2024 Consolidated Leverage Ratio (1) Maximum of 3.50 to 1.00 1.10 to 1.00 Consolidated Interest Coverage Ratio (1) Minimum of 3.00 to 1.00 16.81 to 1.00 ________________________________________ (1)

LEASES

LEASES	9 Months Ended
LEASES	Sep. 30, 2024
Leases [Abstract]
LEASES	LEASES We lease certain warehouse, plant and office facilities, as well as certain equipment, under non-cancelable operating and finance leases expiring at various dates through the year 2042. Most of the operating leases contain renewal options and certain leases include options to purchase the related asset during or at the end of the lease term. Amortization expense related to finance leases is included in depreciation expense, while rent expense related to operating leases is included within cost of sales and selling, research & development and administrative expenses. The components of lease expense for the three and nine months ended September 30, 2024 and 2023 were as follows: Three Months Ended September 30, Nine Months Ended September 30, 2024 2023 2024 2023 Operating lease cost $ 4,795 $ 5,150 $ 14,530 $ 15,841 Finance lease cost: Amortization of right-of-use assets $ 1,715 $ 908 $ 4,976 $ 2,686 Interest on lease liabilities 299 289 897 883 Total finance lease cost $ 2,014 $ 1,197 $ 5,873 $ 3,569 Short-term lease and variable lease costs $ 5,255 $ 5,774 $ 15,451 $ 15,883 Supplemental cash flow information related to leases were as follows: Nine Months Ended September 30, 2024 2023 Cash paid for amounts included in the measurement of lease liabilities: Operating cash flows from operating leases $ 14,845 $ 15,993 Operating cash flows from finance leases 976 883 Financing cash flows from finance leases 2,305 2,377 Right-of-use assets obtained in exchange for lease obligations: Operating leases $ 31,819 $ 7,764 Finance leases 1,347 401
LEASES	LEASES We lease certain warehouse, plant and office facilities, as well as certain equipment, under non-cancelable operating and finance leases expiring at various dates through the year 2042. Most of the operating leases contain renewal options and certain leases include options to purchase the related asset during or at the end of the lease term. Amortization expense related to finance leases is included in depreciation expense, while rent expense related to operating leases is included within cost of sales and selling, research & development and administrative expenses. The components of lease expense for the three and nine months ended September 30, 2024 and 2023 were as follows: Three Months Ended September 30, Nine Months Ended September 30, 2024 2023 2024 2023 Operating lease cost $ 4,795 $ 5,150 $ 14,530 $ 15,841 Finance lease cost: Amortization of right-of-use assets $ 1,715 $ 908 $ 4,976 $ 2,686 Interest on lease liabilities 299 289 897 883 Total finance lease cost $ 2,014 $ 1,197 $ 5,873 $ 3,569 Short-term lease and variable lease costs $ 5,255 $ 5,774 $ 15,451 $ 15,883 Supplemental cash flow information related to leases were as follows: Nine Months Ended September 30, 2024 2023 Cash paid for amounts included in the measurement of lease liabilities: Operating cash flows from operating leases $ 14,845 $ 15,993 Operating cash flows from finance leases 976 883 Financing cash flows from finance leases 2,305 2,377 Right-of-use assets obtained in exchange for lease obligations: Operating leases $ 31,819 $ 7,764 Finance leases 1,347 401

RETIREMENT AND DEFERRED COMPENS

RETIREMENT AND DEFERRED COMPENSATION PLANS	9 Months Ended
RETIREMENT AND DEFERRED COMPENSATION PLANS	Sep. 30, 2024
Retirement Benefits [Abstract]
RETIREMENT AND DEFERRED COMPENSATION PLANS	RETIREMENT AND DEFERRED COMPENSATION PLANS We have various noncontributory retirement plans covering certain of our domestic and foreign employees. Benefits under our retirement plans are based on participants’ years of service and annual compensation as defined by each plan. Annual cash contributions to fund pension costs accrued under our domestic plans are generally at least equal to the minimum funding amounts required by the Employee Retirement Income Security Act of 1974, as amended (“ERISA”). Certain pension commitments under our foreign plans are also funded according to local requirements or at our discretion. Effective January 1, 2021, our domestic noncontributory retirement plans were closed to new employees and employees who were rehired after December 31, 2020. These employees are instead eligible for additional contribution to their defined contribution 401(k) employee savings plan. All domestic employees with hire/rehire dates prior to January 1, 2021 are still eligible for the domestic pension plans and continue to accrue plan benefits after this date. Components of Net Periodic Benefit Cost: Domestic Plans Foreign Plans Three Months Ended September 30, 2024 2023 2024 2023 Service cost $ 2,366 $ 2,409 $ 1,605 $ 1,487 Interest cost 2,242 2,158 860 915 Expected return on plan assets (3,116) (3,094) (549) (589) Amortization of net loss — — 303 230 Amortization of prior service cost — — 29 45 Net periodic benefit cost $ 1,492 $ 1,473 $ 2,248 $ 2,088 Curtailment — — (1,851) — Total Net periodic benefit cost $ 1,492 $ 1,473 $ 397 $ 2,088 Domestic Plans Foreign Plans Nine Months Ended September 30, 2024 2023 2024 2023 Service cost $ 7,097 $ 7,228 $ 4,838 $ 4,444 Interest cost 6,726 6,473 2,602 2,735 Expected return on plan assets (9,347) (9,283) (1,671) (1,758) Amortization of net loss — — 819 687 Amortization of prior service cost — — 83 133 Net periodic benefit cost $ 4,476 $ 4,418 $ 6,671 $ 6,241 Curtailment — — (1,851) — Total Net periodic benefit cost $ 4,476 $ 4,418 $ 4,820 $ 6,241 During the three months ended September 30, 2024, pension curtailment accounting was triggered as a result of restructuring in one of our entities in Europe. The remeasurement of the pension obligations resulted in a decrease of $1.9 million. The components of net periodic benefit cost, other than the service cost component, are included in the line miscellaneous income (expense), net in the Condensed Consolidated Statements of Income. Employer Contributions We currently have no minimum funding requirements for our domestic and foreign plans. There were no contributions to our domestic defined benefit plans during the nine months ended September 30, 2024 and we do not expect significant payments during the rest of 2024. We contributed $2.8 million to our foreign defined benefit plans during the nine months ended September 30, 2024 and do not expect additional significant contributions during the rest of 2024.

ACCUMULATED OTHER COMPREHENSIVE

ACCUMULATED OTHER COMPREHENSIVE (LOSS) INCOME	9 Months Ended
ACCUMULATED OTHER COMPREHENSIVE (LOSS) INCOME	Sep. 30, 2024
Comprehensive Income (Loss), Net of Tax, Attributable to Parent [Abstract]
ACCUMULATED OTHER COMPREHENSIVE (LOSS) INCOME	ACCUMULATED OTHER COMPREHENSIVE (LOSS) INCOME Changes in Accumulated Other Comprehensive (Loss) Income by Component: Foreign Currency Defined Benefit Pension Plans Derivatives Total Balance - December 31, 2022 $ (328,740) $ (5,951) $ (6,675) $ (341,366) Other comprehensive (loss) income before reclassifications (28,294) 63 (2,424) (30,655) Amounts reclassified from accumulated other comprehensive income — 581 — 581 Net current-period other comprehensive (loss) income (28,294) 644 (2,424) (30,074) Balance - September 30, 2023 $ (357,034) $ (5,307) $ (9,099) $ (371,440) Balance - December 31, 2023 $ (280,082) $ (11,891) $ (16,761) $ (308,734) Other comprehensive (loss) income before reclassifications (52) (532) (202) (786) Amounts reclassified from accumulated other comprehensive income — 640 — 640 Net current-period other comprehensive (loss) income (52) 108 (202) (146) Balance - September 30, 2024 $ (280,134) $ (11,783) $ (16,963) $ (308,880) Reclassifications Out of Accumulated Other Comprehensive (Loss) Income: Details about Accumulated Other Amount Reclassified from Accumulated Other Comprehensive Income Affected Line in the Statement Three Months Ended September 30, 2024 2023 Defined Benefit Pension Plans Amortization of net loss $ 303 $ 230 (1) Amortization of prior service cost 29 45 (1) 332 275 Total before tax (96) (81) Tax impact $ 236 $ 194 Net of tax Total reclassifications for the period $ 236 $ 194 Details about Accumulated Other Amount Reclassified from Accumulated Other Comprehensive Income Affected Line in the Statement Nine Months Ended September 30, 2024 2023 Defined Benefit Pension Plans Amortization of net loss $ 819 $ 687 (1) Amortization of prior service cost 83 133 (1) 902 820 Total before tax (262) (239) Tax impact $ 640 $ 581 Net of tax Total reclassifications for the period $ 640 $ 581 ______________________________________________ (1) These accumulated other comprehensive income components are included in the computation of total net periodic benefit costs, net of tax. See Note 8 – Retirement and Deferred Compensation Plans for additional details.

DERIVATIVE INSTRUMENTS AND HEDG

DERIVATIVE INSTRUMENTS AND HEDGING ACTIVITIES	9 Months Ended
DERIVATIVE INSTRUMENTS AND HEDGING ACTIVITIES	Sep. 30, 2024
Derivative Instruments and Hedging Activities Disclosure [Abstract]
DERIVATIVE INSTRUMENTS AND HEDGING ACTIVITIES	DERIVATIVE INSTRUMENTS AND HEDGING ACTIVITIES We maintain a foreign exchange risk management policy designed to establish a framework to protect the value of our non-functional currency denominated transactions from adverse changes in exchange rates. Sales of our products can be denominated in a currency different from the currency in which the related costs to produce the product are denominated. Changes in exchange rates on such inter-country sales or intercompany loans can impact our results of operations. Our policy is not to engage in speculative foreign currency hedging activities, but to minimize our net foreign currency transaction exposure, defined as firm commitments and transactions recorded and denominated in currencies other than the functional currency. We may use foreign currency forward exchange contracts, options and cross currency swaps to economically hedge these risks. For derivative instruments designated as hedges, we formally document the nature and relationships between the hedging instruments and the hedged items, as well as the risk management objectives, strategies for undertaking the various hedge transactions, and the method of assessing hedge effectiveness at inception. Quarterly thereafter, we formally assess whether the derivatives that are used in hedging transactions are highly effective in offsetting changes in the fair value or cash flows of the hedged item. Additionally, in order to designate any derivative instrument as a hedge of an anticipated transaction, the significant characteristics and expected terms of any anticipated transaction must be specifically identified, and it must be probable that the anticipated transaction will occur. All derivative financial instruments used as hedges are recorded at fair value in the Condensed Consolidated Balance Sheets (See Note 11 - Fair Value). Cash Flow Hedge For derivative instruments that are designated and qualify as cash flow hedges, the changes in fair values are recorded in accumulated other comprehensive loss and included in changes in derivative gain/loss. The changes in the fair values of derivatives designated as cash flow hedges are reclassified from accumulated other comprehensive loss to net income when the underlying hedged item is recognized in earnings. Cash flows from the settlement of derivative contracts designated as cash flow hedges offset cash flows from the underlying hedged items and are included in operating activities in the Condensed Consolidated Statements of Cash Flows. Net Investment Hedge A significant number of our operations are located outside of the United States. Because of this, movements in exchange rates may have a significant impact on the translation of the financial condition and results of operations of our foreign subsidiaries. A weakening U.S. dollar has an additive effect on our financial condition and results of operations. Conversely, a strengthening U.S. dollar relative to foreign currencies has a dilutive translation effect. In some cases we maintain debt in these subsidiaries to offset the net asset exposure. In the event we plan on a full or partial liquidation of any of our foreign subsidiaries where our net investment is likely to be monetized, we will consider hedging the currency exposure associated with such a transaction. On July 6, 2022, we entered into a seven-year USD/EUR fixed-to-fixed cross currency interest rate swap to effectively hedge the interest rate exposure relating to $203 million of the $400 million 3.60% Senior Unsecured Notes due March 2032, which were issued by AptarGroup, Inc. on March 7, 2022. This USD/EUR swap agreement exchanged $203 million of fixed-rate 3.60% USD debt to €200 million of fixed-rate 2.5224% euro debt. We pay semi-annual fixed rate interest payments on the euro notional amount of €2.5 million and receive semi-annual fixed rate interest payments on the USD notional amount of $3.7 million. This swap has been designated as a net investment hedge to effectively hedge the foreign exchange risk associated with €200 million of our euro denominated net assets. We elected the spot method for recording the net investment hedge. Gains and losses resulting from the settlement of the excluded components are recorded in interest expense in the Condensed Consolidated Statements of Income. Gains and losses resulting from the fair value adjustments to the cross currency swap agreements are recorded in accumulated other comprehensive (loss) income as the swaps are effective in hedging the designated risk. As of September 30, 2024, the fair value of the cross currency swap was a $22.5 million liability. The swap agreement will mature on September 15, 2029. Other As of September 30, 2024, we have recorded the fair value of foreign currency forward exchange contracts of $0.1 million in prepaid and other and $1.1 million in accounts payable, accrued and other liabilities on the Condensed Consolidated Balance Sheets. All forward exchange contracts outstanding as of September 30, 2024 had an aggregate notional contract amount of $77.2 million. Fair Value of Derivative Instruments in the Condensed Consolidated Balance Sheets as of September 30, 2024 and December 31, 2023 September 30, 2024 December 31, 2023 Balance Sheet Location Derivatives Designated as Hedging Instruments Derivatives not Designated as Hedging Instruments Derivatives Designated as Hedging Instruments Derivatives not Designated as Hedging Instruments Derivative Assets Foreign Exchange Contracts Prepaid and other $ — $ 145 $ — $ 386 $ — $ 145 $ — $ 386 Derivative Liabilities Foreign Exchange Contracts Accounts payable, accrued and other liabilities $ — $ 1,052 $ — $ 221 Cross Currency Swap Contract (1) Accounts payable, accrued and other liabilities 22,466 — 22,199 — $ 22,466 $ 1,052 $ 22,199 $ 221 __________________________ (1) This cross currency swap agreement is composed of both an interest component and a foreign exchange component. The Effect of Derivatives Designated as Hedging Instruments on Accounting on Accumulated Other Comprehensive Income (Loss) for the Three Months Ended September 30, 2024 and 2023 Derivatives Designated as Hedging Instruments Amount of Gain (Loss) Location of (Loss) Amount of Gain (Loss) Total Amount of Affected Income Statement Line Item 2024 2023 2024 2023 Cross currency swap agreement: Interest component $ — $ — Interest expense $ — $ — $ (12,290) Foreign exchange component (5,711) 2,707 Miscellaneous, net — — 1,136 $ (5,711) $ 2,707 $ — $ — The Effect of Derivatives Designated as Hedging Instruments on Accumulated Other Comprehensive Income (Loss) for the Nine Months Ended September 30, 2024 and 2023 Derivatives Designated as Hedging Instruments Amount of Gain Location of Gain Recognized Amount of Gain Total Amount of Affected Income Statement Line Item 2024 2023 2024 2023 Cross currency swap agreement: Interest component $ — $ — Interest expense $ — $ — $ (32,526) Foreign exchange component (202) (2,424) Miscellaneous, net — — (518) $ (202) $ (2,424) $ — $ — The Effect of Derivatives Not Designated as Hedging Instruments on the Condensed Consolidated Statements of Income for the Three Months Ended September 30, 2024 and 2023 Derivatives Not Designated Location of (Loss) Gain Recognized Amount of (Loss) Gain 2024 2023 Foreign Exchange Contracts Other (Expense) Income: $ (1,157) $ 44 $ (1,157) $ 44 The Effect of Derivatives Not Designated as Hedging Instruments on the Condensed Consolidated Statements of Income for the Nine Months Ended September 30, 2024 and 2023 Derivatives Not Designated Location of Loss Recognized Amount of Loss 2024 2023 Foreign Exchange Contracts Other (Expense) Income: $ (1,017) $ (756) $ (1,017) $ (756) Gross Amounts Offset in the Statement of Financial Position Net Amounts Presented in the Statement of Financial Position Gross Amounts not Offset in the Statement of Financial Position Gross Amount Financial Instruments Cash Collateral Received Net Amount September 30, 2024 Derivative Assets $ 145 — $ 145 — — $ 145 Total Assets $ 145 — $ 145 — — $ 145 Derivative Liabilities $ 23,518 — $ 23,518 — — $ 23,518 Total Liabilities $ 23,518 — $ 23,518 — — $ 23,518 December 31, 2023 Derivative Assets $ 386 — $ 386 — — $ 386 Total Assets $ 386 — $ 386 — — $ 386 Derivative Liabilities $ 22,420 — $ 22,420 — — $ 22,420 Total Liabilities $ 22,420 — $ 22,420 — — $ 22,420

FAIR VALUE

FAIR VALUE	9 Months Ended
FAIR VALUE	Sep. 30, 2024
Fair Value Disclosures [Abstract]
FAIR VALUE	FAIR VALUE Authoritative guidelines require the categorization of assets and liabilities into three levels based upon the assumptions (inputs) used to price the assets or liabilities. Level 1 provides the most reliable measure of fair value, whereas Level 3 generally requires significant management judgment. The three levels are defined as follows: • Level 1: Unadjusted quoted prices in active markets for identical assets and liabilities. • Level 2: Observable inputs other than those included in Level 1. For example, quoted prices for similar assets or liabilities in active markets or quoted prices for identical assets or liabilities in inactive markets. • Level 3: Unobservable inputs reflecting management’s own assumptions about the inputs used in pricing the asset or liability. As of September 30, 2024, the fair values of our financial assets and liabilities were categorized as follows: Total Level 1 Level 2 Level 3 Assets Investment in equity securities (1) $ 2,768 $ 2,768 $ — $ — Foreign exchange contracts (2) 145 — 145 — Convertible notes (3) 5,650 — — 5,650 Total assets at fair value $ 8,563 $ 2,768 $ 145 $ 5,650 Liabilities Foreign exchange contracts (2) $ 1,052 $ — $ 1,052 $ — Cross currency swap contract (2) 22,466 — 22,466 — Total liabilities at fair value $ 23,518 $ — $ 23,518 $ — As of December 31, 2023, the fair values of our financial assets and liabilities were categorized as follows: Total Level 1 Level 2 Level 3 Assets Investment in equity securities (1) $ 1,106 $ 1,106 $ — $ — Foreign exchange contracts (2) 386 — 386 — Convertible note (3) 5,650 — — 5,650 Total assets at fair value $ 7,142 $ 1,106 $ 386 $ 5,650 Liabilities Foreign exchange contracts (2) $ 221 $ — $ 221 $ — Cross currency swap contract (2) 22,199 — 22,199 — Total liabilities at fair value $ 22,420 $ — $ 22,420 $ — ________________________________________________ (1) Investment in PureCycle Technologies (“PCT” or “PureCycle”). See Note 18 – Investment in Equity Securities for discussion of this investment. (2) Market approach valuation technique based on observable market transactions of spot and forward rates. (3) Investment in convertible notes in Enable Injections, Inc. and Siklus Refill Pte, Ltd. The investments are included within Miscellaneous assets in our Condensed Consolidated Balance Sheets. The carrying amounts of our other current financial instruments such as cash and equivalents, accounts and notes receivable, notes payable and current maturities of long-term obligations approximate fair value due to the short-term maturity of the instrument. We consider our long-term debt obligations a Level 2 liability and utilize the market approach valuation technique based on interest rates that are currently available to us for issuance of debt with similar terms and maturities. The estimated fair value of our long-term obligations was $775.5 million as of September 30, 2024 and $620.7 million as of December 31, 2023.

COMMITMENTS AND CONTINGENCIES

COMMITMENTS AND CONTINGENCIES	9 Months Ended
COMMITMENTS AND CONTINGENCIES	Sep. 30, 2024
Commitments and Contingencies Disclosure [Abstract]
COMMITMENTS AND CONTINGENCIES	COMMITMENTS AND CONTINGENCIES In the normal course of business, we are subject to a number of lawsuits and claims both actual and potential in nature. While management believes the resolution of these claims and lawsuits will not have a material adverse effect on our financial position, results of operations or cash flows, claims and legal proceedings are subject to inherent uncertainties, and unfavorable outcomes could occur that could include amounts in excess of any accruals which management has established. Were such unfavorable final outcomes to occur, it is possible that they could have a material adverse effect on our financial position, results of operations and cash flows. Under our Certificate of Incorporation, we have agreed to indemnify our officers and directors for certain events or occurrences while the officer or director is, or was, serving at our request in such capacity. The maximum potential amount of future payments we could be required to make under these indemnification agreements is unlimited; however, we have a directors and officers liability insurance policy that covers a portion of our exposure. As a result of our insurance policy coverage, we believe the estimated fair value of these indemnification agreements is minimal. We have no liabilities recorded for these agreements as of September 30, 2024 and December 31, 2023. We are periodically subject to loss contingencies resulting from custom duties assessments. We accrue for anticipated costs when an assessment has indicated that a loss is probable and can be reasonably estimated. We have received claims worth approximately $12 million in principal and $14 million to $15 million for interest and penalties. We are currently defending our position with respect to these claims in the respected administrative procedures. Due to uncertainty in the amount of the assessment and the timing of our appeal, no liability is recorded as of September 30, 2024.

STOCK REPURCHASE PROGRAM

STOCK REPURCHASE PROGRAM	9 Months Ended
STOCK REPURCHASE PROGRAM	Sep. 30, 2024
Equity [Abstract]
STOCK REPURCHASE PROGRAM	STOCK REPURCHASE PROGRAM On April 18, 2019, we announced a share repurchase authorization of up to $350 million of common stock. We may repurchase shares through the open market, privately negotiated transactions or other programs, subject to market conditions. On October 10, 2024, we announced a share repurchase authorization of up to $500 million of common stock. This authorization replaces previous authorizations and has no expiration date.

STOCK-BASED COMPENSATION

STOCK-BASED COMPENSATION	9 Months Ended
STOCK-BASED COMPENSATION	Sep. 30, 2024
Share-Based Payment Arrangement [Abstract]
STOCK-BASED COMPENSATION	STOCK-BASED COMPENSATION We issue restricted stock units (“RSUs”), which consist of time-based and performance-based awards, to employees under stock awards plans approved by stockholders. In addition, RSUs are issued to non-employee directors under a Restricted Stock Unit Award Agreement for Directors pursuant to the Company’s 2018 Equity Incentive Plan. RSUs granted to employees vest according to a specified performance period and/or vesting period. Time-based RSUs generally vest over three years. Performance-based RSUs vest at the end of the specified performance period, generally three years, assuming required performance or market vesting conditions are met. For awards granted in the first quarter of 2023 and thereafter, our performance-based RSUs will vest solely based on our return on invested capital (“ROIC”). Award share payouts depend on the extent to which the ROIC performance goal has been achieved, but the final payout is adjusted by a total shareholder return (“TSR”) modifier. At the time of vesting, the vested shares of common stock are issued in the employee’s name. In addition, RSU awards are generally net settled (shares are withheld to cover the employee tax obligation). RSUs granted to directors are only time-based and generally vest on or around the first anniversary of the date of grant. The fair value of both time-based RSUs and performance-based RSUs pertaining to internal performance metrics is determined using the closing price of our common stock on the grant date. The fair value of performance-based RSUs pertaining to TSR is estimated using a Monte Carlo simulation. Inputs and assumptions used to calculate the fair value are shown in the table below. The fair value of these RSUs is expensed over the vesting period using the straight-line method or using the graded vesting method when an employee becomes eligible to retain the award at retirement. Nine Months Ended September 30, 2024 2023 Fair value per stock award $ 145.79 $ 116.17 Grant date stock price $ 141.00 $ 111.38 Assumptions: Aptar's stock price expected volatility 18.80 % 20.00 % Expected average volatility of peer companies 34.80 % 39.70 % Correlation assumption 30.70 % 33.30 % Risk-free interest rate 4.51 % 3.83 % Dividend yield assumption 1.16 % 1.36 % A summary of RSU activity as of September 30, 2024 and changes during the nine month period then ended is presented below: Time-Based RSUs Performance-Based RSUs Units Weighted Average Units Weighted Average Nonvested at January 1, 2024 335,874 $ 115.15 514,383 $ 130.10 Granted 125,454 137.03 129,614 145.79 Vested (176,820) 119.33 (97,764) 162.33 Forfeited (4,087) 118.06 (32,007) 143.88 Nonvested at September 30, 2024 280,421 $ 122.18 514,226 $ 127.11 Included in the time-based RSU activity for the nine months ended September 30, 2024 are 10,208 units granted to non-employee directors and 11,508 units vested related to non-employee directors. Nine Months Ended September 30, 2024 2023 Compensation expense $ 31,677 $ 32,209 Fair value of units vested 35,434 27,662 Intrinsic value of units vested 38,578 32,319 The actual tax benefit realized for the tax deduction from RSUs was approximately $7.2 million and $5.6 million in the nine months ended September 30, 2024 and 2023, respectively. As of September 30, 2024, there was $51.2 million of total unrecognized compensation cost relating to RSU awards which is expected to be recognized over a weighted-average period of 1.8 years. Historically we issued stock options to our employees and non-employee directors. We did not issue stock options between 2019 and 2022. Stock options were reinstituted in 2023 and valued based on the Black-Scholes model and generally vest ratably over three years and expire 10 years after grant. The Company uses historical data to estimate expected life and volatility. The weighted-average fair value of stock options granted under the stock awards plans were $36.07 per share for all employees during the first nine months of 2024. The weighted-average fair value of stock options granted under the stock awards plans were $19.84 and $24.23 per share for executive officers and all other employees, respectively, during the first nine months of 2023. Aptar executive officers received stock options with an exercise price that was 110% of the closing market price on the date of grant. These values were estimated on the respective dates of grant using the Black-Scholes option-pricing model with the following weighted-average assumptions: Stock Award Plans: Nine Months Ended September 30, 2024 2023 Dividend Yield 1.28 % 1.41 % Expected Stock Price Volatility 17.03 % 16.55 % Risk-free Interest Rate 4.51 % 3.57 % Expected Life of Option (years) 7.0 7.0 A summary of option activity under our stock plans during the nine months ended September 30, 2024 is presented below: Stock Awards Plans Director Stock Option Plans Options Weighted Average Options Weighted Average Outstanding, January 1, 2024 2,182,784 $ 80.63 19,000 $ 66.59 Granted 249,805 141.00 — — Exercised (610,124) 70.98 (19,000) 66.59 Forfeited or expired (9,666) 107.82 — — Outstanding at September 30, 2024 1,812,799 $ 92.05 — $ — Exercisable at September 30, 2024 1,361,396 $ 79.52 — $ — Weighted-Average Remaining Contractual Term (Years): Outstanding at September 30, 2024 4.3 0.0 Exercisable at September 30, 2024 2.7 0.0 Aggregate Intrinsic Value: Outstanding at September 30, 2024 $ 123,515 $ — Exercisable at September 30, 2024 $ 109,830 $ — Intrinsic Value of Options Exercised During the Nine Months Ended: September 30, 2024 $ 43,779 $ 1,394 September 30, 2023 $ 27,392 $ 1,978 Nine Months Ended September 30, 2024 2023 Compensation expense (included in SG&A) $ 5,678 $ 3,561 Compensation expense (included in Cost of sales) 607 314 Compensation expense, Total $ 6,285 $ 3,875 Compensation expense, net of tax 6,121 3,875 Grant date fair value of options vested 2,306 — The increase in stock option expense is due to the newly issued options as discussed above. Cash received from option exercises for the nine months ended September 30, 2024 and 2023 was approximately $44.4 million and $39.7 million, respectively. The actual tax benefit realized for the tax deduction from option exercises was approximately $10.3 million and $6.8 million in the nine months ended September 30, 2024 and 2023, respectively. As of September 30, 2024, there was $5.2 million of total unrecognized compensation cost relating to stock option awards which is expected to be recognized over a weighted-average period of 2.1 years.

EARNINGS PER SHARE

EARNINGS PER SHARE	9 Months Ended
EARNINGS PER SHARE	Sep. 30, 2024
Earnings Per Share [Abstract]
EARNINGS PER SHARE	EARNINGS PER SHARE Basic net income per share is calculated by dividing net income attributable to Aptar by the weighted-average number of common shares outstanding during the period. Diluted net income per share is calculated by dividing the net income attributable to Aptar by the weighted-average number of common and common equivalent shares outstanding during the applicable period. The difference between basic and diluted earnings per share is attributable to stock-based compensation awards. Stock-based compensation awards for which total employee proceeds exceed the average market price over the applicable period would have an antidilutive effect on earnings per share, and accordingly, are excluded from the calculation of diluted earnings per share. The reconciliation of basic and diluted earnings per share for the three and nine months ended September 30, 2024 and 2023 were as follows: Three Months Ended September 30, 2024 September 30, 2023 Diluted Basic Diluted Basic Consolidated operations Income available to common stockholders $ 100,039 $ 100,039 $ 84,296 $ 84,296 Average equivalent shares Shares of common stock 66,445 66,445 65,707 65,707 Effect of dilutive stock-based compensation Stock options 737 — 874 — Restricted stock 534 — 454 — Total average equivalent shares 67,716 66,445 67,035 65,707 Net income per share $ 1.48 $ 1.51 $ 1.26 $ 1.28 Nine Months Ended September 30, 2024 September 30, 2023 Diluted Basic Diluted Basic Consolidated operations Income available to common stockholders $ 273,597 $ 273,597 $ 222,132 $ 222,132 Average equivalent shares Shares of common stock 66,274 66,274 65,550 65,550 Effect of dilutive stock-based compensation Stock options 768 — 886 — Restricted stock 532 — 429 — Total average equivalent shares 67,574 66,274 66,865 65,550 Net income per share $ 4.05 $ 4.13 $ 3.32 $ 3.39

SEGMENT INFORMATION

SEGMENT INFORMATION	9 Months Ended
SEGMENT INFORMATION	Sep. 30, 2024
Segment Reporting [Abstract]
SEGMENT INFORMATION	SEGMENT INFORMATION We are organized into three reporting segments. Operations that sell proprietary dispensing systems, drug delivery systems, sealing solutions and services to the prescription drug, consumer health care, injectables, active material science solutions and digital health markets form our Aptar Pharma segment. Operations that sell dispensing systems and sealing solutions to the beauty, personal care and home care markets form our Aptar Beauty segment. Operations that sell dispensing closures, sealing solutions and food service trays to the food, beverage, personal care, home care, beauty and healthcare markets form our Aptar Closures segment. Aptar Pharma and Aptar Beauty are named for the markets they serve with multiple product platforms, while Aptar Closures is named primarily for a single product platform that serves all available markets. The accounting policies of the segments are the same as those described in Part II, Item 8, Note 1 - Summary of Significant Accounting Policies in our Annual Report on Form 10-K for the year ended December 31, 2023. We evaluate performance of our reporting segments and allocate resources based upon Adjusted EBITDA. Adjusted EBITDA is defined as earnings before net interest, taxes, depreciation, amortization, restructuring initiatives, acquisition-related costs, net unrealized investment gains and losses related to observable market price changes on equity securities and other special items. Financial information regarding our reporting segments is shown below: Three Months Ended Nine Months Ended 2024 2023 2024 2023 Total Sales: Aptar Pharma $ 420,753 $ 389,423 $ 1,243,026 $ 1,136,544 Aptar Beauty 308,955 330,467 972,535 1,002,209 Aptar Closures 187,324 181,562 547,002 539,472 Total Sales $ 917,032 $ 901,452 $ 2,762,563 $ 2,678,225 Less: Intersegment Sales: Aptar Pharma $ 159 $ 235 $ 606 $ 610 Aptar Beauty 6,096 6,487 20,869 22,253 Aptar Closures 1,486 1,733 6,286 6,392 Total Intersegment Sales $ 7,741 $ 8,455 $ 27,761 $ 29,255 Net Sales: Aptar Pharma $ 420,594 $ 389,188 $ 1,242,420 $ 1,135,934 Aptar Beauty 302,859 323,980 951,666 979,956 Aptar Closures 185,838 179,829 540,716 533,080 Net Sales $ 909,291 $ 892,997 $ 2,734,802 $ 2,648,970 Adjusted EBITDA (1): Aptar Pharma $ 151,594 $ 136,344 $ 425,260 $ 371,508 Aptar Beauty 40,221 41,070 125,993 121,375 Aptar Closures 31,980 27,607 86,259 81,387 Corporate & Other, unallocated (15,411) (11,659) (57,528) (45,996) Acquisition-related costs (2) — — (140) (255) Restructuring Initiatives (3) (3,864) (6,161) (9,659) (19,628) Curtailment gain related to restructuring initiatives (5) 1,851 — 1,851 — Net unrealized investment (loss) gain (4) 1,043 (5,428) 1,495 (2,349) Depreciation and amortization (67,015) (62,686) (196,332) (184,212) Interest Expense (12,290) (9,984) (32,526) (29,900) Interest Income 3,022 946 9,022 2,266 Income before Income Taxes $ 131,131 $ 110,049 $ 353,695 $ 294,196 ________________________________________________ (1) We evaluate performance of our reporting segments and allocate resources based upon Adjusted EBITDA. Adjusted EBITDA is defined as earnings before net interest, taxes, depreciation, amortization, restructuring initiatives, acquisition-related costs, net unrealized investment gains and losses related to observable market price changes on equity securities and other special items. (2) Acquisition-related costs include transaction costs (and purchase accounting adjustments related to acquisitions and investments) (see Note 17 - Acquisitions and Note 18 – Investments in Equity Securities for further details). (3) Restructuring Initiatives includes expense items for the three and nine months ended September 30, 2024 and 2023 as follows (see Note 19 – Restructuring Initiatives for further details): Three Months Ended Nine Months Ended 2024 2023 2024 2023 Restructuring Initiatives by Plan: Optimization initiative $ 3,864 $ 6,586 $ 9,676 $ 20,069 Prior year initiatives — (425) (17) (441) Total Restructuring Initiatives $ 3,864 $ 6,161 $ 9,659 $ 19,628 Restructuring Initiatives by Segment: Aptar Pharma $ 564 $ 92 $ 653 $ 1,657 Aptar Beauty 1,962 2,880 5,871 12,650 Aptar Closures 877 3,098 2,530 4,060 Corporate & Other 461 91 605 1,261 Total Restructuring Initiatives $ 3,864 $ 6,161 $ 9,659 $ 19,628 (4) Net unrealized investment (loss) gain represents the change in fair value of our investment in PCT (see Note 18 – Investment in Equity Securities for further details). (5) The curtailment gain is included in the line miscellaneous income (expense), net in the Condensed Consolidated Statements of Income (see Note 8 - Retirement and Deferred Compensation Plans).

ACQUISITIONS

ACQUISITIONS	9 Months Ended
ACQUISITIONS	Sep. 30, 2024
Business Combination, Asset Acquisition, and Joint Venture Formation [Abstract]
ACQUISITIONS	ACQUISITIONS Business Combinations On August 1, 2023, we paid the remaining $5.2 million purchase price in relation to the 2021 Hengyu acquisition. No further liability remains outstanding for this acquisition. On March 1, 2023, we completed the acquisition of all the outstanding capital stock of iD SCENT. Located in Lyon, France, iD SCENT is an expert producer of paper fragrance sampling solutions that present multiple sustainability features. The purchase price was approximately $9.4 million (net of $1.4 million cash acquired) and was funded with cash on hand. The results of iD SCENT have been included in the consolidated financial statements within our Aptar Beauty segment since the date of acquisition. Also on March 1, 2023, we completed the acquisition of 80% of the equity interest of Gulf Closures W.L.L. (“Gulf Closures”). Gulf Closures, located in Bahrain, is a closure manufacturer for beverage products. The purchase price for 80% ownership was approximately $1.5 million (net of $1.2 million cash acquired) and was funded with cash on hand. This values the full company equity at approximately $3.3 million and implies a non-controlling interest valued at approximately $0.7 million as of the acquisition date. The results of Gulf Closures have been included in the consolidated financial statements within our Aptar Closures segment since the date of acquisition.

INVESTMENT IN EQUITY SECURITIES

INVESTMENT IN EQUITY SECURITIES	9 Months Ended
INVESTMENT IN EQUITY SECURITIES	Sep. 30, 2024
Equity Method Investments and Joint Ventures [Abstract]
INVESTMENT IN EQUITY SECURITIES	INVESTMENT IN EQUITY SECURITIES Our investment in equity securities consisted of the following: September 30, December 31, Equity Method Investments: BTY $ 33,069 $ 33,090 Sonmol 4,796 4,751 Desotec GmbH 1,000 905 Other Investments: PureCycle 2,768 1,106 YAT 5,414 5,352 Loop 2,894 2,894 Others 1,111 1,105 $ 51,052 $ 49,203 Equity Method Investments Goldrain On October 22, 2024, we acquired 40% of the equity interests in Ningbo Jinyu Technology Industry Co., Ltd., doing business as Goldrain, (referred to as “Goldrain”), a leading manufacturer of dispensing technologies in China for an approximate purchase price of $99 million. Goldrain is a leading manufacturer specialized in developing and producing packages for skin care, cosmetic, household, cleaning, personal care and perfumery products. BTY On January 1, 2020, we acquired 49% of the equity interests in three related companies: Suzhou Hsing Kwang, Suqian Hsing Kwang and Suzhou BTY (collectively referred to as “BTY”) for an approximate purchase price of $32.0 million. We have a call option to acquire an additional 26% to 31% of BTY’s equity interests following the initial lock-up period of 5 years based on a predetermined formula. Subsequent to the second lock-up period, which ends 3 years after the initial lock-up period, we have a call option to acquire the remaining equity interests of BTY based on a predetermined formula. Additionally, the selling shareholders of BTY have a put option for the remaining equity interest to be acquired by Aptar based on a predetermined formula. The BTY entities are leading Chinese manufacturers of high quality, decorative metal components, metal-plastic sub-assemblies, and complete color cosmetics packaging solutions for the beauty industry. For the nine months ended September 30, 2024 and September 30, 2023, Aptar had purchases of $8.7 million and $10.7 million, respectively, from BTY. As of September 30, 2024 and December 31, 2023, approximately $2.0 million and $1.8 million, respectively, was due to BTY and included in accounts payable, accrued and other liabilities on our Condensed Consolidated Balance Sheets. Sonmol On April 1, 2020, we invested $5.0 million to acquire 30% of the equity interests in Healthcare, Inc., Shanghai Sonmol Internet Technology Co., Ltd. and its subsidiary, Shanghai Sonmol Medical Equipment Co., Ltd. (collectively referred to as “Sonmol”). Sonmol is a leading Chinese pharmaceutical company that provides consumer electric devices and connected devices for asthma control. Desotec GmbH During 2009, we invested €574 thousand to acquire 23% of the equity interests in Desotec GmbH, a leading manufacturer of specialty assembly machines for bulk processing for the pharmaceutical, beauty and closures markets. Other Investments In prior years, we invested, through a series of transactions, an aggregate amount of $2.9 million in preferred equity investments in Loop, a sustainability company. In prior years, we also invested, through a series of transactions, $3.0 million in PureCycle and received $0.7 million of equity in exchange for our resource dedication for technological partnership and support. In March 2021, PureCycle became a publicly-traded company and listed its common stock on Nasdaq under the ticker symbol “PCT,” At that time, our investment in PureCycle was converted into shares of common stock of PCT resulting in less than a 1% ownership interest. This investment is now recorded at fair value based on observable market prices for identical assets and the change in fair value is recorded as a net investment gain or loss in the Condensed Consolidated Statements of Income. We have sold the following PCT shares related to the PureCycle investment: Shares Sold Proceeds Realized Gain 2021 191,349 $ 2,434 $ 2,000 2022 157,600 $ 1,599 $ 1,213 2023 510,449 $ 5,604 $ 4,188 .........................................................................On April 26, 2024, we received $0.2 million of equity in exchange for our resource dedication for technological partnership and support. For the three and nine months ended September 30, 2024 and 2023, we recorded the following net investment gain or loss on our investment in PureCycle: Three Months Ended September 30, Nine Months Ended September 30, 2024 2023 2024 2023 Net investment gain (loss) $ 1,043 $ (1,240) $ 1,495 $ 1,839 On July 7, 2021, we investe d approximately $5.9 million to acquire 10% of the equity interests in YAT, a multi-functional, science-driven online skincare solutions company.

RESTRUCTURING INITIATIVES

RESTRUCTURING INITIATIVES	9 Months Ended
RESTRUCTURING INITIATIVES	Sep. 30, 2024
Restructuring and Related Activities [Abstract]
RESTRUCTURING INITIATIVES	RESTRUCTURING INITIATIVES As part of our ongoing efforts to better leverage our fixed cost base through growth and cost reduction measures, during the three and nine months ended September 30, 2024, we recognized $3.9 million and $9.7 million of restructuring costs related to this initiative, respectively. For the three and nine months ended September 30, 2023, we recognized $6.6 million and $20.1 million of restructuring costs related to this initiative, respectively. The cumulative expense incurred as of September 30, 2024 was $61.3 million. As of September 30, 2024, we have recorded the following activity associated with our optimization initiative: Beginning Reserve at December 31, 2023 Net Charges for the Nine Months Ended September 30, 2024 Cash Paid Interest and Ending Reserve at September 30, 2024 Employee severance $ 27,078 $ 6,003 $ (15,321) $ 38 $ 17,798 Professional fees and other costs 2,810 3,673 (3,560) 36 2,959 Totals $ 29,888 $ 9,676 $ (18,881) $ 74 $ 20,757 During the three months ended September 30, 2024, pension curtailment accounting was triggered as a result of restructuring in one of our entities in Europe. The remeasurement of the pension obligations resulted in a decrease of $1.9 million. The curtailment gain is included in the line miscellaneous income (expense), net in the Condensed Consolidated Statements of Income.

Pay vs Performance Disclosure

Pay vs Performance Disclosure - USD ($) $ in Thousands	3 Months Ended		9 Months Ended
Pay vs Performance Disclosure - USD ($) $ in Thousands	Sep. 30, 2024	Sep. 30, 2023	Sep. 30, 2024	Sep. 30, 2023
Pay vs Performance Disclosure
Net Income (Loss)	$ 100,039	$ 84,296	$ 273,597	$ 222,132

Insider Trading Arrangements

Insider Trading Arrangements	3 Months Ended
Insider Trading Arrangements	Sep. 30, 2024
Trading Arrangements, by Individual
Rule 10b5-1 Arrangement Adopted	false
Non-Rule 10b5-1 Arrangement Adopted	false
Rule 10b5-1 Arrangement Terminated	false
Non-Rule 10b5-1 Arrangement Terminated	false

SUMMARY OF SIGNIFICANT ACCOUN_2

SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (Policies)	9 Months Ended
SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (Policies)	Sep. 30, 2024
Accounting Policies [Abstract]
BASIS OF PRESENTATION	BASIS OF PRESENTATION The accompanying unaudited Condensed Consolidated Financial Statements include the accounts of AptarGroup, Inc. and our subsidiaries. The terms “AptarGroup,” “Aptar,” “Company,” “we,” “us” or “our” as used herein refer to AptarGroup, Inc. and our subsidiaries. All significant intercompany accounts and transactions have been eliminated. Certain previously reported amounts have been reclassified to conform to the current period presentation. In the opinion of management, the unaudited Condensed Consolidated Financial Statements (the “Condensed Consolidated Financial Statements”) include all normal recurring adjustments necessary for a fair statement of consolidated financial position, results of operations, comprehensive income, changes in equity and cash flows for the interim periods presented. The accompanying Condensed Consolidated Financial Statements have been prepared by the Company, pursuant to the rules and regulations of the Securities and Exchange Commission (“SEC”). Certain information and footnote disclosures normally included in financial statements prepared in accordance with accounting principles generally accepted in the United States of America (“U.S. GAAP”) have been condensed or omitted pursuant to such rules and regulations, although we believe that the disclosures made are adequate to make the information presented not misleading. Also, certain financial position data included herein was derived from the audited Consolidated Financial Statements included in our Annual Report on Form 10-K for the year ended December 31, 2023 but does not include all disclosures required by U.S. GAAP. Accordingly, these Condensed Consolidated Financial Statements and related notes should be read in conjunction with the audited Consolidated Financial Statements and notes thereto included in our Annual Report on Form 10-K for the year ended December 31, 2023. The results of operations of any interim period are not necessarily indicative of the results that may be expected for the year.
ADOPTION OF RECENT ACCOUNTING STANDARDS	ADOPTION OF RECENT ACCOUNTING STANDARDS Changes to U.S. GAAP are established by the Financial Accounting Standards Board (“FASB”) in the form of Accounting Standards Updates (“ASUs”) to the FASB’s Accounting Standards Codification. In March 2020, the FASB issued ASU 2020-04, which provides optional expedients and exceptions for applying U.S. GAAP to contracts, hedging relationships and other transactions affected by reference rate reform if certain criteria are met. The amendments to this update apply only to contracts, hedging relationships and other transactions that reference LIBOR or another reference rate expected to be discontinued because of reference rate reform. ASU 2020-04 was further amended in January 2021 by ASU 2021-01 which clarified the applicability of certain provisions. Both standards are effective upon issuance and could be adopted any time prior to December 31, 2022. The guidance in ASU 2020-04 and ASU 2021-01 is optional and may be elected over time as reference rate reform activities occur. We adopted this guidance in the second quarter of 2023 and have transitioned away from the London Interbank Offered Rate (“LIBOR”) to the Secured Overnight Financing Rate (“SOFR”) in our revolving credit facility. In November 2023, the FASB issued ASU 2023-07, Improvement to Reportable Segment Disclosures, which requires enhanced disclosures about significant segment expenses on an annual and interim basis. The amendments in ASU 2023-07 are effective for fiscal years beginning after December 15, 2023 and interim periods within fiscal years beginning after December 15, 2024, with early adoption permitted, and are to be applied on a retrospective basis. We are evaluating the impact of the standard on our segment reporting disclosures. In December 2023, the FASB issued ASU 2023-09, Improvements to Income Tax Disclosures, which is intended to improve income tax disclosure requirements by requiring (i) consistent categories and greater disaggregation of information in the rate reconciliation and (ii) the disaggregation of income taxes paid by jurisdiction. The guidance makes several other changes to income tax disclosure requirements. The amendments in ASU 2023-09 are effective for fiscal years beginning after December 15, 2024, with early adoption permitted, and are required to be applied prospectively with the option of retrospective application. We are evaluating the impact of the standard on our income tax disclosures. Other accounting standards that have been issued by the FASB or other standards-setting bodies did not have a material impact on our Condensed Consolidated Financial Statements.
INCOME TAXES	INCOME TAXES We compute taxes on income in accordance with the tax rules and regulations of the many taxing authorities where income is earned. The income tax rates imposed by these taxing authorities may vary substantially. Taxable income may differ from pre-tax income for U.S. GAAP financial accounting purposes. To the extent that these differences create temporary differences between the tax basis of an asset or liability and our reported amount in the U.S. GAAP financial statements, an appropriate provision for deferred income taxes is made. We maintain our assertion that the cash and distributable reserves at our non-U.S. affiliates are indefinitely reinvested with the following exceptions: all earnings in Germany and the pre-2020 earnings in Italy, Switzerland and Colombia. As of September 30, 2024, under currently enacted laws, we do not have a balance of foreign earnings that will be subject to U.S. taxation upon repatriation. We will provide for the necessary withholding and local income taxes when management decides that an affiliate should make a distribution. These decisions are made taking into consideration the financial requirements of the non-U.S. affiliates and our global cash management goals. See Note 5 – Income Taxes for more information. We provide a liability for the amount of unrecognized tax benefits from uncertain tax positions. This liability is provided whenever we determine that a tax benefit will not meet a more-likely-than-not threshold for recognition. We are subject to the examination of our returns and other tax matters by the U.S. Internal Revenue Service as well as other tax authorities and governmental bodies. We believe that we have adequately provided a tax reserve for any adjustments that may result from tax examinations or uncertain tax positions. However, the outcome of tax audits cannot be predicted with certainty. If any issues addressed in our tax audits are resolved in a manner inconsistent with its expectations, we could be required to adjust its provision for income taxes in the period such resolution occurs. The resolution of each of these audits is not expected to be material to our Condensed Consolidated Financial Statements.
ASSETS HELD FOR SALE	ASSETS HELD FOR SALE Assets to be disposed of by sale are reported at the lower of their carrying amount or fair value less costs to sell, and are not depreciated while they are held for sale. During the second quarter of 2023, we recorded $0.7 million as assets held for sale within prepaid and other on our Condensed Consolidated Balance Sheets related to three buildings located in France. During the third quarter of 2023, two of the three buildings were sold and we recognized a $0.8 million gain on sale. As of September 30, 2024, one building is still held for sale and expected to be sold during 2025.
SUPPLY CHAIN FINANCE PROGRAM	SUPPLY CHAIN FINANCE PROGRAM We facilitate a supply chain finance program (“SCF”) across Europe and the U.S. that is administered by a third-party platform. Eligible suppliers can elect to receive early payment of invoices, less an interest deduction, and negotiate their receivable sales arrangements through the third-party platform on behalf of the respective SCF bank. We are not a party to those agreements, and the terms of our payment obligations are not impacted by a supplier's participation in the SCF. Accordingly, we have concluded that this program continues to be a trade payable program and is not indicative of a borrowing arrangement. Under these agreements, the average payment terms range from 60 to 120 days and are based on industry standards and best practices within each of our regions. All outstanding amounts related to suppliers participating in the SCF are recorded within accounts payable, accrued and other liabilities in our Condensed Consolidated Balance Sheets, and associated payments are included in operating activities within our Condensed Consolidated Statements of Cash Flows. As of September 30, 2024, the amounts due to suppliers participating in the SCF and included in accounts payable, accrued and other liabilities were approximately $35.0 million. Collection and payment periods tend to be longer for our operations located outside the United States due to local business practices. We have also seen an increasing trend in pressure from certain customers to lengthen their payment terms. As the majority of our products are made to order, we have not needed to keep significant amounts of finished goods inventory to meet customer requirements. However, some of our contracts specify an amount of finished goods safety stock we are required to maintain. To the extent our financial position allows and there is a clear financial benefit, we from time-to-time benefit from early payment discounts with some suppliers. We have lengthened the payment terms with our suppliers to be in line with customer trends. While we have offered a third party alternative for our suppliers to receive payments sooner, we generally do not utilize these offerings from our customers as the economic conditions currently are not beneficial for us.

REVENUE (Tables)

REVENUE (Tables)	9 Months Ended
REVENUE (Tables)	Sep. 30, 2024
Revenue from Contract with Customer [Abstract]
Schedule of revenue by segment by geographic area	Revenue by segment and geography based on shipped to locations for the three and nine months ended September 30, 2024 and 2023 were as follows: For the Three Months Ended September 30, 2024 Segment Europe Domestic Latin Asia Total Aptar Pharma $ 204,835 $ 142,747 $ 10,925 $ 62,087 $ 420,594 Aptar Beauty 182,708 59,954 37,565 22,632 302,859 Aptar Closures 57,586 88,870 20,665 18,717 185,838 Total $ 445,129 $ 291,571 $ 69,155 $ 103,436 $ 909,291 For the Three Months Ended September 30, 2023 Segment Europe Domestic Latin Asia Total Aptar Pharma $ 198,546 $ 125,730 $ 13,549 $ 51,363 $ 389,188 Aptar Beauty 201,127 55,674 42,497 24,682 323,980 Aptar Closures 55,508 85,612 21,863 16,846 179,829 Total $ 455,181 $ 267,016 $ 77,909 $ 92,891 $ 892,997 For the Nine Months Ended September 30, 2024 Segment Europe Domestic Latin Asia Total Aptar Pharma $ 624,503 $ 407,291 $ 36,848 $ 173,778 $ 1,242,420 Aptar Beauty 579,638 189,849 117,959 64,220 951,666 Aptar Closures 165,507 262,154 64,221 48,834 540,716 Total $ 1,369,648 $ 859,294 $ 219,028 $ 286,832 $ 2,734,802 For the Nine Months Ended September 30, 2023 Segment Europe Domestic Latin Asia Total Aptar Pharma $ 598,728 $ 354,655 $ 37,415 $ 145,136 $ 1,135,934 Aptar Beauty 622,253 171,602 118,563 67,538 979,956 Aptar Closures 171,645 251,780 63,108 46,547 533,080 Total $ 1,392,626 $ 778,037 $ 219,086 $ 259,221 $ 2,648,970
Schedule of opening and closing balances of contract assets and contract liabilities	The opening and closing balances of our contract asset and contract liabilities were as follows: Balance as of December 31, 2023 Balance as of September 30, 2024 Increase/ Contract asset (current) $ 18,033 $ 15,000 $ (3,033) Contract liability (current) 60,507 64,904 4,397 Contract liability (long-term) 37,756 43,235 5,479

INVENTORIES (Tables)

INVENTORIES (Tables)	9 Months Ended
INVENTORIES (Tables)	Sep. 30, 2024
Inventory Disclosure [Abstract]
Schedule of inventories, by component	Inventories, by component net of reserves, consisted of: September 30, December 31, Raw materials $ 140,194 $ 145,798 Work in process 179,857 176,191 Finished goods 168,489 191,064 Total $ 488,540 $ 513,053

GOODWILL AND OTHER INTANGIBLE_2

GOODWILL AND OTHER INTANGIBLE ASSETS (Tables)	9 Months Ended
GOODWILL AND OTHER INTANGIBLE ASSETS (Tables)	Sep. 30, 2024
Goodwill and Intangible Assets Disclosure [Abstract]
Schedule of changes in the carrying amount of goodwill	The changes in the carrying amount of goodwill for the nine months ended September 30, 2024 by reporting segment were as follows: Aptar Aptar Aptar Closures Total Balance as of December 31, 2023 $ 508,447 $ 287,097 $ 167,874 $ 963,418 Foreign currency exchange effects 4,062 986 (173) 4,875 Balance as of September 30, 2024 $ 512,509 $ 288,083 $ 167,701 $ 968,293
Schedule of amortized intangible assets	The table below shows a summary of intangible assets as of September 30, 2024 and December 31, 2023. September 30, 2024 December 31, 2023 Weighted Average Amortization Period (Years) Gross Accumulated Net Gross Accumulated Net Amortized intangible assets: Patents 12.4 $ 18,862 $ (2,219) $ 16,643 $ 7,362 $ (1,754) $ 5,608 Acquired technology 11.3 143,652 (80,584) 63,068 142,837 (70,520) 72,317 Customer relationships 13.6 310,205 (143,613) 166,592 308,889 (124,648) 184,241 Trademarks and trade names 7.9 44,187 (36,717) 7,470 43,932 (33,368) 10,564 License agreements and other 20.3 26,471 (9,029) 17,442 17,213 (6,732) 10,481 Total intangible assets 13.3 $ 543,377 $ (272,162) $ 271,215 $ 520,233 $ (237,022) $ 283,211
Schedule of future estimated amortization expense	As of September 30, 2024, future estimated amortization expense for the years ending December 31 is as follows: 2024 $ 11,067 (remaining estimated amortization for 2024) 2025 43,616 2026 41,540 2027 33,354 2028 29,203 Thereafter 112,435

DEBT (Tables)

DEBT (Tables)	9 Months Ended
DEBT (Tables)	Sep. 30, 2024
Debt Disclosure [Abstract]
Schedule of short-term debt obligations	At September 30, 2024 and December 31, 2023, our revolving credit facility and overdrafts consisted of the following: September 30, December 31, Revolving credit facility $ 222,650 $ 80,662 Overdraft 167 1,132 $ 222,817 $ 81,794
Schedule of long-term obligations	At September 30, 2024 and December 31, 2023, our long-term obligations consisted of the following: September 30, 2024 December 31, 2023 Notes payable 0.10% – 2.25%, due in monthly and annual installments through 2031 $ 16,893 $ 14,988 Senior unsecured notes 3.4%, due in 2024 — 50,000 Senior unsecured notes 3.5%, due in 2024 — 100,000 Senior unsecured notes 1.2%, due in 2024 — 220,810 Senior unsecured notes 3.6%, due in 2025 125,000 125,000 Senior unsecured notes 3.6%, due in 2026 125,000 125,000 Term loan 6.4% floating, due in 2027 166,000 — Senior unsecured notes 3.6%, due in 2032, net of discount of $0.8 million 399,232 399,154 Finance Lease Liabilities 24,917 26,478 Unamortized debt issuance costs (4,016) (3,816) $ 853,026 $ 1,057,614 Current maturities of long-term obligations (30,295) (376,426) Total long-term obligations $ 822,731 $ 681,188
Schedule of maturities of long-term debt	The aggregate long-term maturities, excluding finance lease liabilities and unamortized debt issuance costs, which are discussed in Note 7, due annually from the current balance sheet date for the next five years and thereafter are: Year One $ 26,912 Year Two 134,438 Year Three 271,276 Year Four 111 Year Five 78 Thereafter 399,310
Schedule of covenants on revolving credit facility and corporate long-term obligations	Our amended revolving credit facility and corporate long-term obligations require us to satisfy certain financial and other covenants including: Requirement Level at September 30, 2024 Consolidated Leverage Ratio (1) Maximum of 3.50 to 1.00 1.10 to 1.00 Consolidated Interest Coverage Ratio (1) Minimum of 3.00 to 1.00 16.81 to 1.00 ________________________________________ (1)

LEASES (Tables)

LEASES (Tables)	9 Months Ended
LEASES (Tables)	Sep. 30, 2024
Leases [Abstract]
Schedule of components of lease expense	The components of lease expense for the three and nine months ended September 30, 2024 and 2023 were as follows: Three Months Ended September 30, Nine Months Ended September 30, 2024 2023 2024 2023 Operating lease cost $ 4,795 $ 5,150 $ 14,530 $ 15,841 Finance lease cost: Amortization of right-of-use assets $ 1,715 $ 908 $ 4,976 $ 2,686 Interest on lease liabilities 299 289 897 883 Total finance lease cost $ 2,014 $ 1,197 $ 5,873 $ 3,569 Short-term lease and variable lease costs $ 5,255 $ 5,774 $ 15,451 $ 15,883
Schedule of supplemental cash flow information related to leases	Supplemental cash flow information related to leases were as follows: Nine Months Ended September 30, 2024 2023 Cash paid for amounts included in the measurement of lease liabilities: Operating cash flows from operating leases $ 14,845 $ 15,993 Operating cash flows from finance leases 976 883 Financing cash flows from finance leases 2,305 2,377 Right-of-use assets obtained in exchange for lease obligations: Operating leases $ 31,819 $ 7,764 Finance leases 1,347 401

RETIREMENT AND DEFERRED COMPE_2

RETIREMENT AND DEFERRED COMPENSATION PLANS (Tables)	9 Months Ended
RETIREMENT AND DEFERRED COMPENSATION PLANS (Tables)	Sep. 30, 2024
Retirement Benefits [Abstract]
Schedule of components of net periodic benefit cost	Components of Net Periodic Benefit Cost: Domestic Plans Foreign Plans Three Months Ended September 30, 2024 2023 2024 2023 Service cost $ 2,366 $ 2,409 $ 1,605 $ 1,487 Interest cost 2,242 2,158 860 915 Expected return on plan assets (3,116) (3,094) (549) (589) Amortization of net loss — — 303 230 Amortization of prior service cost — — 29 45 Net periodic benefit cost $ 1,492 $ 1,473 $ 2,248 $ 2,088 Curtailment — — (1,851) — Total Net periodic benefit cost $ 1,492 $ 1,473 $ 397 $ 2,088 Domestic Plans Foreign Plans Nine Months Ended September 30, 2024 2023 2024 2023 Service cost $ 7,097 $ 7,228 $ 4,838 $ 4,444 Interest cost 6,726 6,473 2,602 2,735 Expected return on plan assets (9,347) (9,283) (1,671) (1,758) Amortization of net loss — — 819 687 Amortization of prior service cost — — 83 133 Net periodic benefit cost $ 4,476 $ 4,418 $ 6,671 $ 6,241 Curtailment — — (1,851) — Total Net periodic benefit cost $ 4,476 $ 4,418 $ 4,820 $ 6,241

ACCUMULATED OTHER COMPREHENSI_2

ACCUMULATED OTHER COMPREHENSIVE (LOSS) INCOME (Tables)	9 Months Ended
ACCUMULATED OTHER COMPREHENSIVE (LOSS) INCOME (Tables)	Sep. 30, 2024
Comprehensive Income (Loss), Net of Tax, Attributable to Parent [Abstract]
Schedule of changes in accumulated other comprehensive (loss) income by component	Changes in Accumulated Other Comprehensive (Loss) Income by Component: Foreign Currency Defined Benefit Pension Plans Derivatives Total Balance - December 31, 2022 $ (328,740) $ (5,951) $ (6,675) $ (341,366) Other comprehensive (loss) income before reclassifications (28,294) 63 (2,424) (30,655) Amounts reclassified from accumulated other comprehensive income — 581 — 581 Net current-period other comprehensive (loss) income (28,294) 644 (2,424) (30,074) Balance - September 30, 2023 $ (357,034) $ (5,307) $ (9,099) $ (371,440) Balance - December 31, 2023 $ (280,082) $ (11,891) $ (16,761) $ (308,734) Other comprehensive (loss) income before reclassifications (52) (532) (202) (786) Amounts reclassified from accumulated other comprehensive income — 640 — 640 Net current-period other comprehensive (loss) income (52) 108 (202) (146) Balance - September 30, 2024 $ (280,134) $ (11,783) $ (16,963) $ (308,880)
Schedule of reclassifications out of accumulated other comprehensive (loss) income	Reclassifications Out of Accumulated Other Comprehensive (Loss) Income: Details about Accumulated Other Amount Reclassified from Accumulated Other Comprehensive Income Affected Line in the Statement Three Months Ended September 30, 2024 2023 Defined Benefit Pension Plans Amortization of net loss $ 303 $ 230 (1) Amortization of prior service cost 29 45 (1) 332 275 Total before tax (96) (81) Tax impact $ 236 $ 194 Net of tax Total reclassifications for the period $ 236 $ 194 Details about Accumulated Other Amount Reclassified from Accumulated Other Comprehensive Income Affected Line in the Statement Nine Months Ended September 30, 2024 2023 Defined Benefit Pension Plans Amortization of net loss $ 819 $ 687 (1) Amortization of prior service cost 83 133 (1) 902 820 Total before tax (262) (239) Tax impact $ 640 $ 581 Net of tax Total reclassifications for the period $ 640 $ 581 ______________________________________________ (1) These accumulated other comprehensive income components are included in the computation of total net periodic benefit costs, net of tax. See Note 8 – Retirement and Deferred Compensation Plans for additional details.

DERIVATIVE INSTRUMENTS AND HE_2

DERIVATIVE INSTRUMENTS AND HEDGING ACTIVITIES (Tables)	9 Months Ended
DERIVATIVE INSTRUMENTS AND HEDGING ACTIVITIES (Tables)	Sep. 30, 2024
Derivative Instruments and Hedging Activities Disclosure [Abstract]
Schedule of fair value of derivative instruments in the consolidated balance sheets	Fair Value of Derivative Instruments in the Condensed Consolidated Balance Sheets as of September 30, 2024 and December 31, 2023 September 30, 2024 December 31, 2023 Balance Sheet Location Derivatives Designated as Hedging Instruments Derivatives not Designated as Hedging Instruments Derivatives Designated as Hedging Instruments Derivatives not Designated as Hedging Instruments Derivative Assets Foreign Exchange Contracts Prepaid and other $ — $ 145 $ — $ 386 $ — $ 145 $ — $ 386 Derivative Liabilities Foreign Exchange Contracts Accounts payable, accrued and other liabilities $ — $ 1,052 $ — $ 221 Cross Currency Swap Contract (1) Accounts payable, accrued and other liabilities 22,466 — 22,199 — $ 22,466 $ 1,052 $ 22,199 $ 221 __________________________ (1) This cross currency swap agreement is composed of both an interest component and a foreign exchange component.
Schedule of effect of cash flow hedge accounting on accumulated other comprehensive income (loss)	The Effect of Derivatives Designated as Hedging Instruments on Accounting on Accumulated Other Comprehensive Income (Loss) for the Three Months Ended September 30, 2024 and 2023 Derivatives Designated as Hedging Instruments Amount of Gain (Loss) Location of (Loss) Amount of Gain (Loss) Total Amount of Affected Income Statement Line Item 2024 2023 2024 2023 Cross currency swap agreement: Interest component $ — $ — Interest expense $ — $ — $ (12,290) Foreign exchange component (5,711) 2,707 Miscellaneous, net — — 1,136 $ (5,711) $ 2,707 $ — $ — The Effect of Derivatives Designated as Hedging Instruments on Accumulated Other Comprehensive Income (Loss) for the Nine Months Ended September 30, 2024 and 2023 Derivatives Designated as Hedging Instruments Amount of Gain Location of Gain Recognized Amount of Gain Total Amount of Affected Income Statement Line Item 2024 2023 2024 2023 Cross currency swap agreement: Interest component $ — $ — Interest expense $ — $ — $ (32,526) Foreign exchange component (202) (2,424) Miscellaneous, net — — (518) $ (202) $ (2,424) $ — $ —
Schedule of effect of derivatives not designated as hedging instruments on the consolidated statements of income	The Effect of Derivatives Not Designated as Hedging Instruments on the Condensed Consolidated Statements of Income for the Three Months Ended September 30, 2024 and 2023 Derivatives Not Designated Location of (Loss) Gain Recognized Amount of (Loss) Gain 2024 2023 Foreign Exchange Contracts Other (Expense) Income: $ (1,157) $ 44 $ (1,157) $ 44 The Effect of Derivatives Not Designated as Hedging Instruments on the Condensed Consolidated Statements of Income for the Nine Months Ended September 30, 2024 and 2023 Derivatives Not Designated Location of Loss Recognized Amount of Loss 2024 2023 Foreign Exchange Contracts Other (Expense) Income: $ (1,017) $ (756) $ (1,017) $ (756)
Schedule of offsetting derivative assets and liabilities	Gross Amounts Offset in the Statement of Financial Position Net Amounts Presented in the Statement of Financial Position Gross Amounts not Offset in the Statement of Financial Position Gross Amount Financial Instruments Cash Collateral Received Net Amount September 30, 2024 Derivative Assets $ 145 — $ 145 — — $ 145 Total Assets $ 145 — $ 145 — — $ 145 Derivative Liabilities $ 23,518 — $ 23,518 — — $ 23,518 Total Liabilities $ 23,518 — $ 23,518 — — $ 23,518 December 31, 2023 Derivative Assets $ 386 — $ 386 — — $ 386 Total Assets $ 386 — $ 386 — — $ 386 Derivative Liabilities $ 22,420 — $ 22,420 — — $ 22,420 Total Liabilities $ 22,420 — $ 22,420 — — $ 22,420

FAIR VALUE (Tables)

FAIR VALUE (Tables)	9 Months Ended
FAIR VALUE (Tables)	Sep. 30, 2024
Fair Value Disclosures [Abstract]
Schedule of fair values of financial assets and liabilities	As of September 30, 2024, the fair values of our financial assets and liabilities were categorized as follows: Total Level 1 Level 2 Level 3 Assets Investment in equity securities (1) $ 2,768 $ 2,768 $ — $ — Foreign exchange contracts (2) 145 — 145 — Convertible notes (3) 5,650 — — 5,650 Total assets at fair value $ 8,563 $ 2,768 $ 145 $ 5,650 Liabilities Foreign exchange contracts (2) $ 1,052 $ — $ 1,052 $ — Cross currency swap contract (2) 22,466 — 22,466 — Total liabilities at fair value $ 23,518 $ — $ 23,518 $ — As of December 31, 2023, the fair values of our financial assets and liabilities were categorized as follows: Total Level 1 Level 2 Level 3 Assets Investment in equity securities (1) $ 1,106 $ 1,106 $ — $ — Foreign exchange contracts (2) 386 — 386 — Convertible note (3) 5,650 — — 5,650 Total assets at fair value $ 7,142 $ 1,106 $ 386 $ 5,650 Liabilities Foreign exchange contracts (2) $ 221 $ — $ 221 $ — Cross currency swap contract (2) 22,199 — 22,199 — Total liabilities at fair value $ 22,420 $ — $ 22,420 $ — ________________________________________________ (1) Investment in PureCycle Technologies (“PCT” or “PureCycle”). See Note 18 – Investment in Equity Securities for discussion of this investment. (2) Market approach valuation technique based on observable market transactions of spot and forward rates. (3) Investment in convertible notes in Enable Injections, Inc. and Siklus Refill Pte, Ltd. The investments are included within Miscellaneous assets in our Condensed Consolidated Balance Sheets.

STOCK-BASED COMPENSATION (Table

STOCK-BASED COMPENSATION (Tables)	9 Months Ended
STOCK-BASED COMPENSATION (Tables)	Sep. 30, 2024
Share-Based Payment Arrangement [Abstract]
Schedule of weighted-average assumptions used to estimate fair value of restricted stock units	Inputs and assumptions used to calculate the fair value are shown in the table below. The fair value of these RSUs is expensed over the vesting period using the straight-line method or using the graded vesting method when an employee becomes eligible to retain the award at retirement. Nine Months Ended September 30, 2024 2023 Fair value per stock award $ 145.79 $ 116.17 Grant date stock price $ 141.00 $ 111.38 Assumptions: Aptar's stock price expected volatility 18.80 % 20.00 % Expected average volatility of peer companies 34.80 % 39.70 % Correlation assumption 30.70 % 33.30 % Risk-free interest rate 4.51 % 3.83 % Dividend yield assumption 1.16 % 1.36 %
Schedule of restricted stock unit activity	A summary of RSU activity as of September 30, 2024 and changes during the nine month period then ended is presented below: Time-Based RSUs Performance-Based RSUs Units Weighted Average Units Weighted Average Nonvested at January 1, 2024 335,874 $ 115.15 514,383 $ 130.10 Granted 125,454 137.03 129,614 145.79 Vested (176,820) 119.33 (97,764) 162.33 Forfeited (4,087) 118.06 (32,007) 143.88 Nonvested at September 30, 2024 280,421 $ 122.18 514,226 $ 127.11
Schedule of compensation expense, fair value, and intrinsic value related to RSU's	Nine Months Ended September 30, 2024 2023 Compensation expense $ 31,677 $ 32,209 Fair value of units vested 35,434 27,662 Intrinsic value of units vested 38,578 32,319
Schedule of share-based payment award, stock options, valuation assumptions	These values were estimated on the respective dates of grant using the Black-Scholes option-pricing model with the following weighted-average assumptions: Stock Award Plans: Nine Months Ended September 30, 2024 2023 Dividend Yield 1.28 % 1.41 % Expected Stock Price Volatility 17.03 % 16.55 % Risk-free Interest Rate 4.51 % 3.57 % Expected Life of Option (years) 7.0 7.0
Schedule of option activity	A summary of option activity under our stock plans during the nine months ended September 30, 2024 is presented below: Stock Awards Plans Director Stock Option Plans Options Weighted Average Options Weighted Average Outstanding, January 1, 2024 2,182,784 $ 80.63 19,000 $ 66.59 Granted 249,805 141.00 — — Exercised (610,124) 70.98 (19,000) 66.59 Forfeited or expired (9,666) 107.82 — — Outstanding at September 30, 2024 1,812,799 $ 92.05 — $ — Exercisable at September 30, 2024 1,361,396 $ 79.52 — $ — Weighted-Average Remaining Contractual Term (Years): Outstanding at September 30, 2024 4.3 0.0 Exercisable at September 30, 2024 2.7 0.0 Aggregate Intrinsic Value: Outstanding at September 30, 2024 $ 123,515 $ — Exercisable at September 30, 2024 $ 109,830 $ — Intrinsic Value of Options Exercised During the Nine Months Ended: September 30, 2024 $ 43,779 $ 1,394 September 30, 2023 $ 27,392 $ 1,978
Schedule of compensation expense, and fair value related to options	Nine Months Ended September 30, 2024 2023 Compensation expense (included in SG&A) $ 5,678 $ 3,561 Compensation expense (included in Cost of sales) 607 314 Compensation expense, Total $ 6,285 $ 3,875 Compensation expense, net of tax 6,121 3,875 Grant date fair value of options vested 2,306 —

EARNINGS PER SHARE (Tables)

EARNINGS PER SHARE (Tables)	9 Months Ended
EARNINGS PER SHARE (Tables)	Sep. 30, 2024
Earnings Per Share [Abstract]
Schedule of reconciliation of basic and diluted earnings per share	The reconciliation of basic and diluted earnings per share for the three and nine months ended September 30, 2024 and 2023 were as follows: Three Months Ended September 30, 2024 September 30, 2023 Diluted Basic Diluted Basic Consolidated operations Income available to common stockholders $ 100,039 $ 100,039 $ 84,296 $ 84,296 Average equivalent shares Shares of common stock 66,445 66,445 65,707 65,707 Effect of dilutive stock-based compensation Stock options 737 — 874 — Restricted stock 534 — 454 — Total average equivalent shares 67,716 66,445 67,035 65,707 Net income per share $ 1.48 $ 1.51 $ 1.26 $ 1.28 Nine Months Ended September 30, 2024 September 30, 2023 Diluted Basic Diluted Basic Consolidated operations Income available to common stockholders $ 273,597 $ 273,597 $ 222,132 $ 222,132 Average equivalent shares Shares of common stock 66,274 66,274 65,550 65,550 Effect of dilutive stock-based compensation Stock options 768 — 886 — Restricted stock 532 — 429 — Total average equivalent shares 67,574 66,274 66,865 65,550 Net income per share $ 4.05 $ 4.13 $ 3.32 $ 3.39

SEGMENT INFORMATION (Tables)

SEGMENT INFORMATION (Tables)	9 Months Ended
SEGMENT INFORMATION (Tables)	Sep. 30, 2024
Segment Reporting [Abstract]
Schedule of financial information regarding the company's reportable segments	Financial information regarding our reporting segments is shown below: Three Months Ended Nine Months Ended 2024 2023 2024 2023 Total Sales: Aptar Pharma $ 420,753 $ 389,423 $ 1,243,026 $ 1,136,544 Aptar Beauty 308,955 330,467 972,535 1,002,209 Aptar Closures 187,324 181,562 547,002 539,472 Total Sales $ 917,032 $ 901,452 $ 2,762,563 $ 2,678,225 Less: Intersegment Sales: Aptar Pharma $ 159 $ 235 $ 606 $ 610 Aptar Beauty 6,096 6,487 20,869 22,253 Aptar Closures 1,486 1,733 6,286 6,392 Total Intersegment Sales $ 7,741 $ 8,455 $ 27,761 $ 29,255 Net Sales: Aptar Pharma $ 420,594 $ 389,188 $ 1,242,420 $ 1,135,934 Aptar Beauty 302,859 323,980 951,666 979,956 Aptar Closures 185,838 179,829 540,716 533,080 Net Sales $ 909,291 $ 892,997 $ 2,734,802 $ 2,648,970 Adjusted EBITDA (1): Aptar Pharma $ 151,594 $ 136,344 $ 425,260 $ 371,508 Aptar Beauty 40,221 41,070 125,993 121,375 Aptar Closures 31,980 27,607 86,259 81,387 Corporate & Other, unallocated (15,411) (11,659) (57,528) (45,996) Acquisition-related costs (2) — — (140) (255) Restructuring Initiatives (3) (3,864) (6,161) (9,659) (19,628) Curtailment gain related to restructuring initiatives (5) 1,851 — 1,851 — Net unrealized investment (loss) gain (4) 1,043 (5,428) 1,495 (2,349) Depreciation and amortization (67,015) (62,686) (196,332) (184,212) Interest Expense (12,290) (9,984) (32,526) (29,900) Interest Income 3,022 946 9,022 2,266 Income before Income Taxes $ 131,131 $ 110,049 $ 353,695 $ 294,196 ________________________________________________ (1) We evaluate performance of our reporting segments and allocate resources based upon Adjusted EBITDA. Adjusted EBITDA is defined as earnings before net interest, taxes, depreciation, amortization, restructuring initiatives, acquisition-related costs, net unrealized investment gains and losses related to observable market price changes on equity securities and other special items. (2) Acquisition-related costs include transaction costs (and purchase accounting adjustments related to acquisitions and investments) (see Note 17 - Acquisitions and Note 18 – Investments in Equity Securities for further details). (3) Restructuring Initiatives includes expense items for the three and nine months ended September 30, 2024 and 2023 as follows (see Note 19 – Restructuring Initiatives for further details): Three Months Ended Nine Months Ended 2024 2023 2024 2023 Restructuring Initiatives by Plan: Optimization initiative $ 3,864 $ 6,586 $ 9,676 $ 20,069 Prior year initiatives — (425) (17) (441) Total Restructuring Initiatives $ 3,864 $ 6,161 $ 9,659 $ 19,628 Restructuring Initiatives by Segment: Aptar Pharma $ 564 $ 92 $ 653 $ 1,657 Aptar Beauty 1,962 2,880 5,871 12,650 Aptar Closures 877 3,098 2,530 4,060 Corporate & Other 461 91 605 1,261 Total Restructuring Initiatives $ 3,864 $ 6,161 $ 9,659 $ 19,628 (4) Net unrealized investment (loss) gain represents the change in fair value of our investment in PCT (see Note 18 – Investment in Equity Securities for further details). (5) The curtailment gain is included in the line miscellaneous income (expense), net in the Condensed Consolidated Statements of Income (see Note 8 - Retirement and Deferred Compensation Plans).
Schedule of restructuring initiatives	Restructuring Initiatives includes expense items for the three and nine months ended September 30, 2024 and 2023 as follows (see Note 19 – Restructuring Initiatives for further details): Three Months Ended Nine Months Ended 2024 2023 2024 2023 Restructuring Initiatives by Plan: Optimization initiative $ 3,864 $ 6,586 $ 9,676 $ 20,069 Prior year initiatives — (425) (17) (441) Total Restructuring Initiatives $ 3,864 $ 6,161 $ 9,659 $ 19,628 Restructuring Initiatives by Segment: Aptar Pharma $ 564 $ 92 $ 653 $ 1,657 Aptar Beauty 1,962 2,880 5,871 12,650 Aptar Closures 877 3,098 2,530 4,060 Corporate & Other 461 91 605 1,261 Total Restructuring Initiatives $ 3,864 $ 6,161 $ 9,659 $ 19,628

INVESTMENT IN EQUITY SECURITI_2

INVESTMENT IN EQUITY SECURITIES (Tables)	9 Months Ended
INVESTMENT IN EQUITY SECURITIES (Tables)	Sep. 30, 2024
Equity Method Investments and Joint Ventures [Abstract]
Schedule of investments in equity securities	Our investment in equity securities consisted of the following: September 30, December 31, Equity Method Investments: BTY $ 33,069 $ 33,090 Sonmol 4,796 4,751 Desotec GmbH 1,000 905 Other Investments: PureCycle 2,768 1,106 YAT 5,414 5,352 Loop 2,894 2,894 Others 1,111 1,105 $ 51,052 $ 49,203
Schedule of sale of PCT shares related to Purecycle investment	We have sold the following PCT shares related to the PureCycle investment: Shares Sold Proceeds Realized Gain 2021 191,349 $ 2,434 $ 2,000 2022 157,600 $ 1,599 $ 1,213 2023 510,449 $ 5,604 $ 4,188
Schedule of net investment gain/loss	For the three and nine months ended September 30, 2024 and 2023, we recorded the following net investment gain or loss on our investment in PureCycle: Three Months Ended September 30, Nine Months Ended September 30, 2024 2023 2024 2023 Net investment gain (loss) $ 1,043 $ (1,240) $ 1,495 $ 1,839

RESTRUCTURING INITIATIVES (Tabl

RESTRUCTURING INITIATIVES (Tables)	9 Months Ended
RESTRUCTURING INITIATIVES (Tables)	Sep. 30, 2024
Restructuring and Related Activities [Abstract]
Schedule of activity associated with optimization initiative	As of September 30, 2024, we have recorded the following activity associated with our optimization initiative: Beginning Reserve at December 31, 2023 Net Charges for the Nine Months Ended September 30, 2024 Cash Paid Interest and Ending Reserve at September 30, 2024 Employee severance $ 27,078 $ 6,003 $ (15,321) $ 38 $ 17,798 Professional fees and other costs 2,810 3,673 (3,560) 36 2,959 Totals $ 29,888 $ 9,676 $ (18,881) $ 74 $ 20,757

SUMMARY OF SIGNIFICANT ACCOUN_3

SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES - Narrative (Details) $ in Millions	3 Months Ended	9 Months Ended
	Sep. 30, 2023 USD ($) building	Sep. 30, 2024 USD ($) building	Jun. 30, 2023 USD ($) building
Product Information [Line Items]
Assets held-for-sale			$ 0.7
Number of buildings held before the sale \| building	3	1	3
Number of buildings sold \| building	2
Gain on sale of buildings	$ 0.8
Supplier finance program obligation, current		$ 35
Minimum
Product Information [Line Items]
Supplier finance program payment terms		60 days
Maximum
Product Information [Line Items]
Supplier finance program payment terms		120 days

REVENUE - Revenue by Geographic

REVENUE - Revenue by Geographic Segment (Details) - USD ($) $ in Thousands	3 Months Ended		9 Months Ended
	Sep. 30, 2024	Sep. 30, 2023	Sep. 30, 2024	Sep. 30, 2023
REVENUE
Total	$ 909,291	$ 892,997	$ 2,734,802	$ 2,648,970
Aptar Pharma
REVENUE
Total	420,594	389,188	1,242,420	1,135,934
Aptar Beauty
REVENUE
Total	302,859	323,980	951,666	979,956
Aptar Closures
REVENUE
Total	185,838	179,829	540,716	533,080
Europe
REVENUE
Total	445,129	455,181	1,369,648	1,392,626
Europe \| Aptar Pharma
REVENUE
Total	204,835	198,546	624,503	598,728
Europe \| Aptar Beauty
REVENUE
Total	182,708	201,127	579,638	622,253
Europe \| Aptar Closures
REVENUE
Total	57,586	55,508	165,507	171,645
Domestic
REVENUE
Total	291,571	267,016	859,294	778,037
Domestic \| Aptar Pharma
REVENUE
Total	142,747	125,730	407,291	354,655
Domestic \| Aptar Beauty
REVENUE
Total	59,954	55,674	189,849	171,602
Domestic \| Aptar Closures
REVENUE
Total	88,870	85,612	262,154	251,780
Latin America
REVENUE
Total	69,155	77,909	219,028	219,086
Latin America \| Aptar Pharma
REVENUE
Total	10,925	13,549	36,848	37,415
Latin America \| Aptar Beauty
REVENUE
Total	37,565	42,497	117,959	118,563
Latin America \| Aptar Closures
REVENUE
Total	20,665	21,863	64,221	63,108
Asia
REVENUE
Total	103,436	92,891	286,832	259,221
Asia \| Aptar Pharma
REVENUE
Total	62,087	51,363	173,778	145,136
Asia \| Aptar Beauty
REVENUE
Total	22,632	24,682	64,220	67,538
Asia \| Aptar Closures
REVENUE
Total	$ 18,717	$ 16,846	$ 48,834	$ 46,547

REVENUE - Contract Assets and C

REVENUE - Contract Assets and Contract Liabilities (Details) - USD ($) $ in Thousands	9 Months Ended
	Sep. 30, 2024	Dec. 31, 2023
Revenue from Contract with Customer [Abstract]
Contract asset (current)	$ 15,000	$ 18,033
Increase / (decrease) in Contract asset (current)	(3,033)
Contract liability (current)	64,904	60,507
Increase / (decrease) in Contract liability (current)	4,397
Contract liability (long-term)	43,235	$ 37,756
Increase / (decrease) in Contract liability (long-term)	5,479
Revenue recognized previously included in current contract liabilities	76,500
Revenue recognized previously included in current contract liabilities at the beginning of the year	$ 40,200

INVENTORIES (Details)

INVENTORIES (Details) - USD ($) $ in Thousands	Sep. 30, 2024	Dec. 31, 2023
Inventories, by component
Raw materials	$ 140,194	$ 145,798
Work in process	179,857	176,191
Finished goods	168,489	191,064
Total	$ 488,540	$ 513,053

GOODWILL AND OTHER INTANGIBLE_3

GOODWILL AND OTHER INTANGIBLE ASSETS - Schedule of Goodwill (Details) $ in Thousands	9 Months Ended
	Sep. 30, 2024 USD ($)
Changes in the carrying amount of goodwill
Goodwill, beginning balance	$ 963,418
Foreign currency exchange effects	4,875
Goodwill, ending balance	968,293
Operating segment \| Aptar Pharma
Changes in the carrying amount of goodwill
Goodwill, beginning balance	508,447
Foreign currency exchange effects	4,062
Goodwill, ending balance	512,509
Operating segment \| Aptar Beauty
Changes in the carrying amount of goodwill
Goodwill, beginning balance	287,097
Foreign currency exchange effects	986
Goodwill, ending balance	288,083
Operating segment \| Aptar Closures
Changes in the carrying amount of goodwill
Goodwill, beginning balance	167,874
Foreign currency exchange effects	(173)
Goodwill, ending balance	$ 167,701

GOODWILL AND OTHER INTANGIBLE_4

GOODWILL AND OTHER INTANGIBLE ASSETS - Summary of Intangible Assets (Details) - USD ($) $ in Thousands	3 Months Ended		9 Months Ended
	Sep. 30, 2024	Sep. 30, 2023	Sep. 30, 2024	Sep. 30, 2023	Dec. 31, 2023
Amortized intangible assets
Gross Carrying Amount	$ 543,377		$ 543,377		$ 520,233
Accumulated Amortization	(272,162)		(272,162)		(237,022)
Net Value	271,215		271,215		283,211
Aggregate amortization expense	$ 11,733	$ 11,400	$ 33,407	$ 33,494
Weighted Average Amortization Period (Years)
Amortized intangible assets
Weighted Average Amortization Period (Years)	13 years 3 months 18 days		13 years 3 months 18 days
Patents
Amortized intangible assets
Gross Carrying Amount	$ 18,862		$ 18,862		7,362
Accumulated Amortization	(2,219)		(2,219)		(1,754)
Net Value	$ 16,643		$ 16,643		5,608
Patents \| Weighted Average Amortization Period (Years)
Amortized intangible assets
Weighted Average Amortization Period (Years)	12 years 4 months 24 days		12 years 4 months 24 days
Acquired technology
Amortized intangible assets
Gross Carrying Amount	$ 143,652		$ 143,652		142,837
Accumulated Amortization	(80,584)		(80,584)		(70,520)
Net Value	$ 63,068		$ 63,068		72,317
Acquired technology \| Weighted Average Amortization Period (Years)
Amortized intangible assets
Weighted Average Amortization Period (Years)	11 years 3 months 18 days		11 years 3 months 18 days
Customer relationships
Amortized intangible assets
Gross Carrying Amount	$ 310,205		$ 310,205		308,889
Accumulated Amortization	(143,613)		(143,613)		(124,648)
Net Value	$ 166,592		$ 166,592		184,241
Customer relationships \| Weighted Average Amortization Period (Years)
Amortized intangible assets
Weighted Average Amortization Period (Years)	13 years 7 months 6 days		13 years 7 months 6 days
Trademarks and trade names
Amortized intangible assets
Gross Carrying Amount	$ 44,187		$ 44,187		43,932
Accumulated Amortization	(36,717)		(36,717)		(33,368)
Net Value	$ 7,470		$ 7,470		10,564
Trademarks and trade names \| Weighted Average Amortization Period (Years)
Amortized intangible assets
Weighted Average Amortization Period (Years)	7 years 10 months 24 days		7 years 10 months 24 days
License agreements and other
Amortized intangible assets
Gross Carrying Amount	$ 26,471		$ 26,471		17,213
Accumulated Amortization	(9,029)		(9,029)		(6,732)
Net Value	$ 17,442		$ 17,442		$ 10,481
License agreements and other \| Weighted Average Amortization Period (Years)
Amortized intangible assets
Weighted Average Amortization Period (Years)	20 years 3 months 18 days		20 years 3 months 18 days

GOODWILL AND OTHER INTANGIBLE_5

GOODWILL AND OTHER INTANGIBLE ASSETS - Future Amortization Expense (Details) $ in Thousands	Sep. 30, 2024 USD ($)
Goodwill and Intangible Assets Disclosure [Abstract]
2024	$ 11,067
2025	43,616
2026	41,540
2027	33,354
2028	29,203
Thereafter	$ 112,435

INCOME TAXES (Details)

INCOME TAXES (Details)	3 Months Ended		9 Months Ended
INCOME TAXES (Details)	Sep. 30, 2024	Sep. 30, 2023	Sep. 30, 2024	Sep. 30, 2023
Income Tax Disclosure [Abstract]
Effective income tax rate	23.80%	23.40%	22.70%	24.60%

DEBT - Short-term Debt Obligati

DEBT - Short-term Debt Obligations (Details) - USD ($) $ in Thousands	Sep. 30, 2024	Dec. 31, 2023
Short-term Debt [Line Items]
Revolving credit facility and overdrafts	$ 222,817	$ 81,794
Revolving credit facility
Short-term Debt [Line Items]
Revolving credit facility and overdrafts	222,650	80,662
Overdraft
Short-term Debt [Line Items]
Revolving credit facility and overdrafts	$ 167	$ 1,132

DEBT - Narrative (Details)

DEBT - Narrative (Details) € in Millions	Sep. 05, 2024 USD ($)	Jul. 19, 2024 EUR (€)	Jul. 02, 2024 USD ($) extension	Feb. 26, 2024 USD ($)	Sep. 30, 2024 USD ($)	Sep. 30, 2024 EUR (€)	Jul. 01, 2024 USD ($)	Dec. 31, 2023 USD ($)	Dec. 31, 2023 EUR (€)
Line of Credit Facility [Line Items]
Short-term borrowing					$ 222,817,000			$ 81,794,000
Commercial Paper
Line of Credit Facility [Line Items]
Short-term borrowing, maximum borrowing capacity					30,000,000
Short-term borrowing					0			0
Amended Revolving Credit Facility
Line of Credit Facility [Line Items]
Line of credit facility, maximum borrowing capacity							$ 600,000,000
Line of credit facility, increase limit							$ 300,000,000
Amended Revolving Credit Facility Maturing In July 2029
Line of Credit Facility [Line Items]
Line of credit facility, number of extensions \| extension			2
Line of credit facility, duration of extension (in years)			1 year
Long-term line of credit								36,500,000
Compensating balance, amount					0
Amended Revolving Credit Facility Maturing In July 2029 \| Revolving Credit Facility
Line of Credit Facility [Line Items]
Long-term line of credit					222,700,000	€ 200		44,200,000	€ 40
Amended Revolving Credit Facility Maturing In July 2029 \| Subsidiaries
Line of Credit Facility [Line Items]
Long-term line of credit					0			0
Term loan 6.4% floating, due in 2027
Line of Credit Facility [Line Items]
Line of credit facility, maximum borrowing capacity			$ 330,000,000
Long-term debt, gross					$ 166,000,000			$ 0
Interest rate on notes					6.40%	6.40%
Senior Unsecured Notes 3.49% Due In 2024
Line of Credit Facility [Line Items]
Debt instrument, repaid				$ 100,000,000
Interest rate on notes				3.49%
Senior Unsecured Notes 1.17% Due In 2024
Line of Credit Facility [Line Items]
Debt instrument, repaid \| €		€ 200
Interest rate on notes		1.17%
Senior Unsecured Notes 3.4% Due In September 2024
Line of Credit Facility [Line Items]
Debt instrument, repaid	$ 50,000,000
Interest rate on notes	3.40%

DEBT - Long-Term Obligations (D

DEBT - Long-Term Obligations (Details) - USD ($) $ in Thousands	Sep. 30, 2024	Dec. 31, 2023	Jul. 06, 2022
Components of the company's debt obligations
Finance Lease Liabilities	$ 24,917	$ 26,478
Unamortized debt issuance costs	(4,016)	(3,816)
Long-term debt and lease obligation, including current maturities	853,026	1,057,614
Current maturities of long-term obligations	(30,295)	(376,426)
Total long-term obligations	822,731	681,188
Notes payable 0.10% – 2.25%, due in monthly and annual installments through 2031
Components of the company's debt obligations
Long-term debt, gross	$ 16,893	14,988
Notes payable 0.10% – 2.25%, due in monthly and annual installments through 2031 \| Minimum
Components of the company's debt obligations
Interest rate on notes	0.10%
Notes payable 0.10% – 2.25%, due in monthly and annual installments through 2031 \| Maximum
Components of the company's debt obligations
Interest rate on notes	2.25%
Senior unsecured notes 3.4%, due in 2024
Components of the company's debt obligations
Long-term debt, gross	$ 0	50,000
Interest rate on notes	3.40%
Senior unsecured notes 3.5%, due in 2024
Components of the company's debt obligations
Long-term debt, gross	$ 0	100,000
Interest rate on notes	3.50%
Senior unsecured notes 1.2%, due in 2024
Components of the company's debt obligations
Long-term debt, gross	$ 0	220,810
Interest rate on notes	1.20%
Senior unsecured notes 3.6%, due in 2025
Components of the company's debt obligations
Long-term debt, gross	$ 125,000	125,000
Interest rate on notes	3.60%
Senior unsecured notes 3.6%, due in 2026
Components of the company's debt obligations
Long-term debt, gross	$ 125,000	125,000
Interest rate on notes	3.60%
Term loan 6.4% floating, due in 2027
Components of the company's debt obligations
Long-term debt, gross	$ 166,000	0
Interest rate on notes	6.40%
Senior unsecured notes 3.6%, due in 2032, net of discount of $0.8 million
Components of the company's debt obligations
Long-term debt, gross	$ 399,232	$ 399,154
Interest rate on notes	3.60%		3.60%
Debt instrument, discount	$ 800

DEBT - Long-Term Maturities (De

DEBT - Long-Term Maturities (Details) $ in Thousands	Sep. 30, 2024 USD ($)
Debt Disclosure [Abstract]
Year One	$ 26,912
Year Two	134,438
Year Three	271,276
Year Four	111
Year Five	78
Thereafter	$ 399,310

DEBT - Covenants (Details)

DEBT - Covenants (Details)	Sep. 30, 2024
Line of Credit Facility [Line Items]
Consolidated Leverage Ratio	1.10
Consolidated Interest Coverage Ratio	16.81
Minimum
Line of Credit Facility [Line Items]
Consolidated Interest Coverage Ratio	3
Maximum
Line of Credit Facility [Line Items]
Consolidated Leverage Ratio	3.50

LEASES - Components of Lease Ex

LEASES - Components of Lease Expense (Details) - USD ($) $ in Thousands	3 Months Ended		9 Months Ended
	Sep. 30, 2024	Sep. 30, 2023	Sep. 30, 2024	Sep. 30, 2023
Components of lease expense:
Operating lease cost	$ 4,795	$ 5,150	$ 14,530	$ 15,841
Finance lease cost:
Amortization of right-of-use assets	1,715	908	4,976	2,686
Interest on lease liabilities	299	289	897	883
Total finance lease cost	2,014	1,197	5,873	3,569
Short-term lease and variable lease costs	$ 5,255	$ 5,774	$ 15,451	$ 15,883

LEASES - Supplemental Cash Flow

LEASES - Supplemental Cash Flow Information (Details) - USD ($) $ in Thousands	9 Months Ended
	Sep. 30, 2024	Sep. 30, 2023
Cash paid for amounts included in the measurement of lease liabilities:
Operating cash flows from operating leases	$ 14,845	$ 15,993
Operating cash flows from finance leases	976	883
Financing cash flows from finance leases	2,305	2,377
Right-of-use assets obtained in exchange for lease obligations:
Operating leases	31,819	7,764
Finance leases	$ 1,347	$ 401

RETIREMENT AND DEFERRED COMPE_3

RETIREMENT AND DEFERRED COMPENSATION PLANS - Components of Net Periodic Benefit Cost (Details) - USD ($) $ in Thousands	3 Months Ended		9 Months Ended
	Sep. 30, 2024	Sep. 30, 2023	Sep. 30, 2024	Sep. 30, 2023
Components of net periodic benefit cost:
Curtailment	$ (1,851)	$ 0	$ (1,851)	$ 0
United States
Components of net periodic benefit cost:
Service cost	2,366	2,409	7,097	7,228
Interest cost	2,242	2,158	6,726	6,473
Expected return on plan assets	(3,116)	(3,094)	(9,347)	(9,283)
Amortization of net loss	0	0	0	0
Amortization of prior service cost	0	0	0	0
Net periodic benefit cost	1,492	1,473	4,476	4,418
Curtailment	0	0	0	0
Total Net periodic benefit cost	1,492	1,473	4,476	4,418
Foreign Plans
Components of net periodic benefit cost:
Service cost	1,605	1,487	4,838	4,444
Interest cost	860	915	2,602	2,735
Expected return on plan assets	(549)	(589)	(1,671)	(1,758)
Amortization of net loss	303	230	819	687
Amortization of prior service cost	29	45	83	133
Net periodic benefit cost	2,248	2,088	6,671	6,241
Curtailment	(1,851)	0	(1,851)	0
Total Net periodic benefit cost	$ 397	$ 2,088	$ 4,820	$ 6,241

RETIREMENT AND DEFERRED COMPE_4

RETIREMENT AND DEFERRED COMPENSATION PLANS - Narrative (Details) - USD ($)	3 Months Ended		9 Months Ended
	Sep. 30, 2024	Sep. 30, 2023	Sep. 30, 2024	Sep. 30, 2023
Changes in the benefit obligations and plan assets
Curtailment gain related to restructuring initiatives	$ 1,851,000	$ 0	$ 1,851,000	$ 0
Minimum funding requirements			0
United States
Changes in the benefit obligations and plan assets
Curtailment gain related to restructuring initiatives	0	0	0	0
Defined benefit plan, plan assets, contributions by employer			0
Foreign Plans
Changes in the benefit obligations and plan assets
Curtailment gain related to restructuring initiatives	$ 1,851,000	$ 0	1,851,000	$ 0
Defined benefit plan, plan assets, contributions by employer			$ 2,800,000

ACCUMULATED OTHER COMPREHENSI_3

ACCUMULATED OTHER COMPREHENSIVE (LOSS) INCOME - Changes in Accumulated Other Comprehensive Income by Component (Details) - USD ($) $ in Thousands	9 Months Ended
	Sep. 30, 2024	Sep. 30, 2023
Accumulated other comprehensive income activity
Balance at the beginning of the period	$ 2,306,824
Other comprehensive (loss) income before reclassifications	(786)	$ (30,655)
Amounts reclassified from accumulated other comprehensive income	640	581
Net current-period other comprehensive (loss) income	(146)	(30,074)
Balance at the end of the period	2,539,009
Accumulated Other Comprehensive Income/(Loss)
Accumulated other comprehensive income activity
Balance at the beginning of the period	(308,734)	(341,366)
Balance at the end of the period	(308,880)	(371,440)
Foreign Currency
Accumulated other comprehensive income activity
Balance at the beginning of the period	(280,082)	(328,740)
Other comprehensive (loss) income before reclassifications	(52)	(28,294)
Amounts reclassified from accumulated other comprehensive income	0	0
Net current-period other comprehensive (loss) income	(52)	(28,294)
Balance at the end of the period	(280,134)	(357,034)
Defined Benefit Pension Plans
Accumulated other comprehensive income activity
Balance at the beginning of the period	(11,891)	(5,951)
Other comprehensive (loss) income before reclassifications	(532)	63
Amounts reclassified from accumulated other comprehensive income	640	581
Net current-period other comprehensive (loss) income	108	644
Balance at the end of the period	(11,783)	(5,307)
Derivatives
Accumulated other comprehensive income activity
Balance at the beginning of the period	(16,761)	(6,675)
Other comprehensive (loss) income before reclassifications	(202)	(2,424)
Amounts reclassified from accumulated other comprehensive income	0	0
Net current-period other comprehensive (loss) income	(202)	(2,424)
Balance at the end of the period	$ (16,963)	$ (9,099)

ACCUMULATED OTHER COMPREHENSI_4

ACCUMULATED OTHER COMPREHENSIVE (LOSS) INCOME - Reclassifications From Accumulated Other Comprehensive Income (Details) - USD ($) $ in Thousands	3 Months Ended		9 Months Ended
	Sep. 30, 2024	Sep. 30, 2023	Sep. 30, 2024	Sep. 30, 2023
Amount Reclassified from Accumulated Other Comprehensive Income
Total before tax	$ (131,131)	$ (110,049)	$ (353,695)	$ (294,196)
Tax impact	31,209	25,751	80,382	72,265
Total reclassifications for the period	(99,922)	(84,298)	(273,313)	(221,931)
Amount Reclassified from Accumulated Other Comprehensive Income
Amount Reclassified from Accumulated Other Comprehensive Income
Total reclassifications for the period	236	194	640	581
Defined Benefit Pension Plans \| Amount Reclassified from Accumulated Other Comprehensive Income
Amount Reclassified from Accumulated Other Comprehensive Income
Amortization of net loss	303	230	819	687
Amortization of prior service cost	29	45	83	133
Total before tax	332	275	902	820
Tax impact	(96)	(81)	(262)	(239)
Total reclassifications for the period	$ 236	$ 194	$ 640	$ 581

DERIVATIVE INSTRUMENTS AND HE_3

DERIVATIVE INSTRUMENTS AND HEDGING ACTIVITIES - Narrative (Details) $ in Thousands, € in Millions	Jul. 06, 2022 EUR (€)	Sep. 30, 2024 USD ($)	Dec. 31, 2023 USD ($)	Jul. 06, 2022 USD ($)	Jul. 06, 2022 EUR (€)
Derivative Instruments and Hedging Activities Disclosures [Line Items]
Derivative Assets		$ 145	$ 386
Derivative Liabilities		23,518	22,420
Derivatives not Designated as Hedging Instruments
Derivative Instruments and Hedging Activities Disclosures [Line Items]
Derivative Assets		145	386
Derivative Liabilities		1,052	221
Cross Currency Swap Contract \| Accounts payable, accrued and other liabilities \| Derivatives not Designated as Hedging Instruments
Derivative Instruments and Hedging Activities Disclosures [Line Items]
Derivative Liabilities		0	0
Cross Currency Swap Contract \| Net Investment Hedging
Derivative Instruments and Hedging Activities Disclosures [Line Items]
Derivative, term of contract	7 years
Amount hedged				$ 203,000	€ 200
Derivative fixed interest rate				2.5224%	2.5224%
Derivative, annual fixed interest payments receivable				$ 3,700
Cash flow hedge derivative instrument liability at fair value		22,500
Foreign Exchange Contracts
Derivative Instruments and Hedging Activities Disclosures [Line Items]
Derivative, notional amount		77,200
Foreign Exchange Contracts \| Prepaid and other \| Derivatives not Designated as Hedging Instruments
Derivative Instruments and Hedging Activities Disclosures [Line Items]
Derivative Assets		145	386
Foreign Exchange Contracts \| Accounts payable, accrued and other liabilities \| Derivatives not Designated as Hedging Instruments
Derivative Instruments and Hedging Activities Disclosures [Line Items]
Derivative Liabilities		$ 1,052	$ 221
Senior unsecured notes 3.6%, due in 2032, net of discount of $0.8 million
Derivative Instruments and Hedging Activities Disclosures [Line Items]
Debt instrument, face amount				$ 400,000
Interest rate on notes		3.60%		3.60%	3.60%
Debt instrument, periodic payment \| €	€ 2.5

DERIVATIVE INSTRUMENTS AND HE_4

DERIVATIVE INSTRUMENTS AND HEDGING ACTIVITIES - Fair Value of Derivative Instruments in the Consolidated Balance Sheets (Details) - USD ($) $ in Thousands	Sep. 30, 2024	Dec. 31, 2023
Fair Value of Derivative Instruments
Derivative Assets	$ 145	$ 386
Derivative Liabilities	23,518	22,420
Derivatives Designated as Hedging Instruments
Fair Value of Derivative Instruments
Derivative Assets	0	0
Derivative Liabilities	22,466	22,199
Derivatives Designated as Hedging Instruments \| Foreign Exchange Contracts \| Prepaid and other
Fair Value of Derivative Instruments
Derivative Assets	0	0
Derivatives Designated as Hedging Instruments \| Foreign Exchange Contracts \| Accounts payable, accrued and other liabilities
Fair Value of Derivative Instruments
Derivative Liabilities	0	0
Derivatives Designated as Hedging Instruments \| Cross Currency Swap Contract \| Accounts payable, accrued and other liabilities
Fair Value of Derivative Instruments
Derivative Liabilities	22,466	22,199
Derivatives not Designated as Hedging Instruments
Fair Value of Derivative Instruments
Derivative Assets	145	386
Derivative Liabilities	1,052	221
Derivatives not Designated as Hedging Instruments \| Foreign Exchange Contracts \| Prepaid and other
Fair Value of Derivative Instruments
Derivative Assets	145	386
Derivatives not Designated as Hedging Instruments \| Foreign Exchange Contracts \| Accounts payable, accrued and other liabilities
Fair Value of Derivative Instruments
Derivative Liabilities	1,052	221
Derivatives not Designated as Hedging Instruments \| Cross Currency Swap Contract \| Accounts payable, accrued and other liabilities
Fair Value of Derivative Instruments
Derivative Liabilities	$ 0	$ 0

DERIVATIVE INSTRUMENTS AND HE_5

DERIVATIVE INSTRUMENTS AND HEDGING ACTIVITIES - Effect of Cash Flow Hedge Accounting on Accumulated Other Comprehensive Income (Details) - USD ($) $ in Thousands	3 Months Ended		9 Months Ended
	Sep. 30, 2024	Sep. 30, 2023	Sep. 30, 2024	Sep. 30, 2023
Derivative instruments, gain or (loss)
Interest expense	$ (12,290)	$ (9,984)	$ (32,526)	$ (29,900)
Miscellaneous income (expense), net	1,136	3	(518)	(1,341)
Derivatives in Cash Flow Hedging Relationships
Derivative instruments, gain or (loss)
Amount of Gain (Loss) Recognized in Other Comprehensive Income on Derivative	(5,711)	2,707	(202)	(2,424)
Amount of Gain (Loss) Reclassified from Accumulated Other Comprehensive Income on Derivative	0	0	0	0
Changes in cross currency swap: interest component \| Derivatives in Cash Flow Hedging Relationships
Derivative instruments, gain or (loss)
Interest expense	(12,290)		(32,526)
Changes in cross currency swap: interest component \| Interest expense \| Derivatives in Cash Flow Hedging Relationships
Derivative instruments, gain or (loss)
Amount of Gain (Loss) Recognized in Other Comprehensive Income on Derivative	0	0	0	0
Amount of Gain (Loss) Reclassified from Accumulated Other Comprehensive Income on Derivative	0	0	0	0
Changes in cross currency swap: foreign exchange component \| Derivatives in Cash Flow Hedging Relationships
Derivative instruments, gain or (loss)
Miscellaneous income (expense), net	1,136		(518)
Changes in cross currency swap: foreign exchange component \| Miscellaneous, net \| Derivatives in Cash Flow Hedging Relationships
Derivative instruments, gain or (loss)
Amount of Gain (Loss) Recognized in Other Comprehensive Income on Derivative	(5,711)	2,707	(202)	(2,424)
Amount of Gain (Loss) Reclassified from Accumulated Other Comprehensive Income on Derivative	$ 0	$ 0	$ 0	$ 0

DERIVATIVE INSTRUMENTS AND HE_6

DERIVATIVE INSTRUMENTS AND HEDGING ACTIVITIES - Effect of Derivatives Not Designated as Hedging Instruments on the Condensed Consolidated Statement of Income (Details) - USD ($) $ in Thousands	3 Months Ended		9 Months Ended
	Sep. 30, 2024	Sep. 30, 2023	Sep. 30, 2024	Sep. 30, 2023
Derivative Instruments and Hedging Activities Disclosures [Line Items]
Amount of (Loss) Gain Recognized in Income on Derivatives	$ (1,157)	$ 44	$ (1,017)	$ (756)
Foreign Exchange Contracts
Derivative Instruments and Hedging Activities Disclosures [Line Items]
Amount of (Loss) Gain Recognized in Income on Derivatives	$ (1,157)	$ 44	$ (1,017)	$ (756)

DERIVATIVE INSTRUMENTS AND HE_7

DERIVATIVE INSTRUMENTS AND HEDGING ACTIVITIES - Schedule of Derivative Assets and Liabilities (Details) - USD ($) $ in Thousands	Sep. 30, 2024	Dec. 31, 2023
Derivative Assets
Gross Amount	$ 145	$ 386
Gross Amounts Offset in the Statement of Financial Position	0	0
Net Amounts Presented in the Statement of Financial Position	145	386
Gross Amounts not Offset in the Statement of Financial Position, Financial Instruments	0	0
Gross Amounts not Offset in the Statement of Financial Position, Cash Collateral Received	0	0
Net Amount	$ 145	$ 386
Derivative Asset, Statement of Financial Position [Extensible Enumeration]	Prepaid and other	Prepaid and other
Derivative Liabilities
Gross Amount	$ 23,518	$ 22,420
Gross Amounts Offset in the Statement of Financial Position	0	0
Net Amounts Presented in the Statement of Financial Position	23,518	22,420
Gross Amounts not Offset in the Statement of Financial Position, Financial Instruments	0	0
Gross Amounts not Offset in the Statement of Financial Position, Cash Collateral Received	0	0
Net Amount	$ 23,518	$ 22,420
Derivative Liability, Statement of Financial Position [Extensible Enumeration]	Accounts payable, accrued and other liabilities	Accounts payable, accrued and other liabilities

FAIR VALUE - Fair Value of Fina

FAIR VALUE - Fair Value of Financial Assets and Liabilities (Details) - Assets and liabilities measured at fair value on recurring basis - USD ($) $ in Thousands	Sep. 30, 2024	Dec. 31, 2023
Assets
Investment in equity securities	$ 2,768	$ 1,106
Foreign exchange contracts	145	386
Convertible notes	5,650	5,650
Total assets at fair value	8,563	7,142
Liabilities
Foreign exchange contracts	1,052	221
Cross currency swap contract	22,466	22,199
Total liabilities at fair value	23,518	22,420
Level 1
Assets
Investment in equity securities	2,768	1,106
Foreign exchange contracts	0	0
Convertible notes	0	0
Total assets at fair value	2,768	1,106
Liabilities
Foreign exchange contracts	0	0
Cross currency swap contract	0	0
Total liabilities at fair value	0	0
Level 2
Assets
Investment in equity securities	0	0
Foreign exchange contracts	145	386
Convertible notes	0	0
Total assets at fair value	145	386
Liabilities
Foreign exchange contracts	1,052	221
Cross currency swap contract	22,466	22,199
Total liabilities at fair value	23,518	22,420
Level 3
Assets
Investment in equity securities	0	0
Foreign exchange contracts	0	0
Convertible notes	5,650	5,650
Total assets at fair value	5,650	5,650
Liabilities
Foreign exchange contracts	0	0
Cross currency swap contract	0	0
Total liabilities at fair value	$ 0	$ 0

FAIR VALUE - Narrative (Details

FAIR VALUE - Narrative (Details) - USD ($) $ in Millions	Sep. 30, 2024	Dec. 31, 2023
Fair Value Disclosures [Abstract]
Fair value of long-term obligations	$ 775.5	$ 620.7

COMMITMENTS AND CONTINGENCIES (

COMMITMENTS AND CONTINGENCIES (Details) - USD ($)	Sep. 30, 2024	Dec. 31, 2023
Indemnification agreements
Commitments and contingencies
Liabilities recorded under indemnification agreements	$ 0	$ 0
Tax Assessment
Commitments and contingencies
Loss contingency estimate of possible loss	12,000,000
Loss contingency liability recorded	0
Tax Assessment, Interest and Penalties \| Minimum
Commitments and contingencies
Loss contingency estimate of possible loss	14,000,000
Tax Assessment, Interest and Penalties \| Maximum
Commitments and contingencies
Loss contingency estimate of possible loss	$ 15,000,000

STOCK REPURCHASE PROGRAM (Detai

STOCK REPURCHASE PROGRAM (Details) - USD ($) shares in Thousands, $ in Millions	3 Months Ended		9 Months Ended
	Sep. 30, 2024	Sep. 30, 2023	Sep. 30, 2024	Sep. 30, 2023	Oct. 10, 2024	Apr. 18, 2019
Stock repurchase program
Common stock repurchased (retired and held in treasury) (in shares)	95	66	215	318
Common stock repurchased (retired and held in treasury)	$ 14.2	$ 8.3	$ 31.3	$ 37.3
Stock Repurchase Program April 18, 2019
Stock repurchase program
Share repurchases authorized amount						$ 350
Stock Repurchase Program October 10, 2024 \| Subsequent Event
Stock repurchase program
Share repurchases authorized amount					$ 500

STOCK-BASED COMPENSATION - Narr

STOCK-BASED COMPENSATION - Narrative (Details) - USD ($) $ / shares in Units, $ in Thousands	9 Months Ended
	Sep. 30, 2024	Sep. 30, 2023
Share-based Compensation Arrangement by Share-based Payment Award
Weighted average fair value of stock options granted (in dollars per share)	$ 36.07
Proceeds from stock option exercises	$ 44,364	$ 39,742
Executive Officer
Share-based Compensation Arrangement by Share-based Payment Award
Weighted average fair value of stock options granted (in dollars per share)		$ 19.84
Received stock options exercise price percentage		110%
Non Executive Officer Employees
Share-based Compensation Arrangement by Share-based Payment Award
Weighted average fair value of stock options granted (in dollars per share)		$ 24.23
Time-Based RSUs
Share-based Compensation Arrangement by Share-based Payment Award
Vesting period (in years)	3 years
RSU's granted (in shares)	125,454
RSUs vested (in shares)	176,820
Time-Based RSUs \| Director Stock Option Plans
Share-based Compensation Arrangement by Share-based Payment Award
RSU's granted (in shares)	10,208
RSUs vested (in shares)	11,508
Performance-Based RSUs
Share-based Compensation Arrangement by Share-based Payment Award
Vesting period (in years)	3 years
RSU's granted (in shares)	129,614
RSUs vested (in shares)	97,764
Restricted Stock Units
Share-based Compensation Arrangement by Share-based Payment Award
Tax benefit	$ 7,200	$ 5,600
Unrecognized compensation expense	$ 51,200
Weighted-average period cost will be recognized over	1 year 9 months 18 days
Options
Share-based Compensation Arrangement by Share-based Payment Award
Vesting period (in years)	3 years
Tax benefit	$ 10,300	6,800
Unrecognized compensation expense	$ 5,200
Weighted-average period cost will be recognized over	2 years 1 month 6 days
Expiration period (in years)	10 years
Proceeds from stock option exercises	$ 44,400	$ 39,700

STOCK-BASED COMPENSATION - Assu

STOCK-BASED COMPENSATION - Assumptions Used (Details) - Performance-Based RSUs - $ / shares	9 Months Ended
	Sep. 30, 2024	Sep. 30, 2023
Share-based Compensation Arrangement by Share-based Payment Award
Fair value per stock award (in dollars per share)	$ 145.79	$ 116.17
Grant date stock price (in dollars per share)	$ 141	$ 111.38
Aptar's stock price expected volatility	18.80%	20%
Expected average volatility of peer companies	34.80%	39.70%
Correlation assumption	30.70%	33.30%
Risk-free interest rate	4.51%	3.83%
Dividend yield assumption	1.16%	1.36%

STOCK-BASED COMPENSATION - Rest

STOCK-BASED COMPENSATION - Restricted Stock Unit Activity (Details)	9 Months Ended
	Sep. 30, 2024 $ / shares shares
Time-Based RSUs
Units
Nonvested outstanding beginning balance (in shares) \| shares	335,874
Granted (in shares) \| shares	125,454
Vested (in shares) \| shares	(176,820)
Forfeited (in shares) \| shares	(4,087)
Nonvested outstanding ending balance (in shares) \| shares	280,421
Weighted Average Grant-Date Fair Value
Outstanding, Weighted average grant date fair value begging balance (in dollars per share) \| $ / shares	$ 115.15
Granted, Weighted average grant date fair value (in dollars per share) \| $ / shares	137.03
Vested, Weighted average grant date fair value (in dollars per share) \| $ / shares	119.33
Forfeited, Weighted average grant date fair value (in dollars per share) \| $ / shares	118.06
Outstanding, Weighted average grant date fair value ending balance (in dollars per share) \| $ / shares	$ 122.18
Performance-Based RSUs
Units
Nonvested outstanding beginning balance (in shares) \| shares	514,383
Granted (in shares) \| shares	129,614
Vested (in shares) \| shares	(97,764)
Forfeited (in shares) \| shares	(32,007)
Nonvested outstanding ending balance (in shares) \| shares	514,226
Weighted Average Grant-Date Fair Value
Outstanding, Weighted average grant date fair value begging balance (in dollars per share) \| $ / shares	$ 130.10
Granted, Weighted average grant date fair value (in dollars per share) \| $ / shares	145.79
Vested, Weighted average grant date fair value (in dollars per share) \| $ / shares	162.33
Forfeited, Weighted average grant date fair value (in dollars per share) \| $ / shares	143.88
Outstanding, Weighted average grant date fair value ending balance (in dollars per share) \| $ / shares	$ 127.11

STOCK-BASED COMPENSATION - Comp

STOCK-BASED COMPENSATION - Compensation Expense (Details) - USD ($) $ in Thousands	9 Months Ended
	Sep. 30, 2024	Sep. 30, 2023
Restricted Stock Units
Share-based Compensation Arrangement by Share-based Payment Award
Compensation expense	$ 31,677	$ 32,209
Fair value of units vested	35,434	27,662
Intrinsic value of units vested	38,578	32,319
Options
Share-based Compensation Arrangement by Share-based Payment Award
Compensation expense	6,285	3,875
Compensation expense, net of tax	6,121	3,875
Grant date fair value of options vested	2,306	0
Options \| Compensation expense (included in SG&A)
Share-based Compensation Arrangement by Share-based Payment Award
Compensation expense	5,678	3,561
Options \| Compensation expense (included in Cost of sales)
Share-based Compensation Arrangement by Share-based Payment Award
Compensation expense	$ 607	$ 314

STOCK-BASED COMPENSATION - Sche

STOCK-BASED COMPENSATION - Schedule of Option Activity (Details) - Options - USD ($) $ / shares in Units, $ in Thousands	9 Months Ended
	Sep. 30, 2024	Sep. 30, 2023
Stock Awards Plans
Assumptions used to estimate fair value of stock options granted
Dividend yield assumption	1.28%	1.41%
Expected Stock Price Volatility	17.03%	16.55%
Risk-free interest rate	4.51%	3.57%
Expected Life of Option (years)	7 years	7 years
Stock options activity
Outstanding at the beginning of the period (in shares)	2,182,784
Granted (in shares)	249,805
Exercised (in shares)	(610,124)
Forfeited or expired (in shares)	(9,666)
Outstanding at the end of the period (in shares)	1,812,799
Stock option weighted average exercise price
Outstanding at the beginning of the period (in dollars per share)	$ 80.63
Options granted, Weighted average exercise price (in dollars per share)	141
Options exercised, Weighted average exercise price (in dollars per share)	70.98
Options forfeited or expired, Weighted average exercise price (in dollars per share)	107.82
Outstanding at the end of the period (in dollars per share)	$ 92.05
Share-based Compensation Arrangement by Share-based Payment Award, Options, Additional Disclosures [Abstract]
Options exercisable, Number of options (in shares)	1,361,396
Options exercisable, Weighted average exercise price (in dollars per share)	$ 79.52
Options outstanding, Weighted average remaining contractual term (in years)	4 years 3 months 18 days
Options exercisable, Weighted average remaining contractual term (in years)	2 years 8 months 12 days
Options outstanding, Aggregate intrinsic value	$ 123,515
Options exercisable, Aggregate intrinsic value	109,830
Options exercised, Intrinsic value, at end of period	$ 43,779	$ 27,392
Director Stock Option Plans
Stock options activity
Outstanding at the beginning of the period (in shares)	19,000
Granted (in shares)	0
Exercised (in shares)	(19,000)
Forfeited or expired (in shares)	0
Outstanding at the end of the period (in shares)	0
Stock option weighted average exercise price
Outstanding at the beginning of the period (in dollars per share)	$ 66.59
Options granted, Weighted average exercise price (in dollars per share)	0
Options exercised, Weighted average exercise price (in dollars per share)	66.59
Options forfeited or expired, Weighted average exercise price (in dollars per share)	0
Outstanding at the end of the period (in dollars per share)	$ 0
Share-based Compensation Arrangement by Share-based Payment Award, Options, Additional Disclosures [Abstract]
Options exercisable, Number of options (in shares)	0
Options exercisable, Weighted average exercise price (in dollars per share)	$ 0
Options outstanding, Weighted average remaining contractual term (in years)	0 years
Options exercisable, Weighted average remaining contractual term (in years)	0 years
Options outstanding, Aggregate intrinsic value	$ 0
Options exercisable, Aggregate intrinsic value	0
Options exercised, Intrinsic value, at end of period	$ 1,394	$ 1,978

EARNINGS PER SHARE (Details)

EARNINGS PER SHARE (Details) - USD ($) $ / shares in Units, shares in Thousands, $ in Thousands	3 Months Ended		9 Months Ended
	Sep. 30, 2024	Sep. 30, 2023	Sep. 30, 2024	Sep. 30, 2023
Consolidated operations
Income available to common stockholders, diluted	$ 100,039	$ 84,296	$ 273,597	$ 222,132
Income available to common stockholders, basic	$ 100,039	$ 84,296	$ 273,597	$ 222,132
Average equivalent shares (in Shares)
Basic (in shares)	66,445	65,707	66,274	65,550
Effect of dilutive stock-based compensation
Diluted (in shares)	67,716	67,035	67,574	66,865
Net income per share
Net income per share, diluted (in dollars per share)	$ 1.48	$ 1.26	$ 4.05	$ 3.32
Net income per share, basic (in dollars per share)	$ 1.51	$ 1.28	$ 4.13	$ 3.39
Stock options
Effect of dilutive stock-based compensation
Incremental common shares attributable to dilutive effect of share-based payment arrangements (in shares)	737	874	768	886
Restricted stock
Effect of dilutive stock-based compensation
Incremental common shares attributable to dilutive effect of share-based payment arrangements (in shares)	534	454	532	429

SEGMENT INFORMATION - Schedule

SEGMENT INFORMATION - Schedule of Reportable Segments (Details) $ in Thousands	3 Months Ended		9 Months Ended
	Sep. 30, 2024 USD ($)	Sep. 30, 2023 USD ($)	Sep. 30, 2024 USD ($) segment	Sep. 30, 2023 USD ($)
Segment Reporting [Abstract]
Number of reportable segments \| segment			3
Financial information regarding the Company's reportable segments
Net Sales	$ 909,291	$ 892,997	$ 2,734,802	$ 2,648,970
Acquisition-related costs	0	0	(140)	(255)
Restructuring Initiatives	(3,864)	(6,161)	(9,659)	(19,628)
Curtailment gain related to restructuring initiatives	1,851	0	1,851	0
Net unrealized investment (loss) gain	1,043	(5,428)	1,495	(2,349)
Depreciation and amortization	(67,015)	(62,686)	(196,332)	(184,212)
Interest Expense	(12,290)	(9,984)	(32,526)	(29,900)
Interest Income	3,022	946	9,022	2,266
Income before Income Taxes	131,131	110,049	353,695	294,196
Optimization initiative
Financial information regarding the Company's reportable segments
Restructuring Initiatives	(3,864)	(6,586)	(9,676)	(20,069)
Prior year initiatives
Financial information regarding the Company's reportable segments
Restructuring Initiatives	0	425	17	441
Aptar Pharma
Financial information regarding the Company's reportable segments
Net Sales	420,594	389,188	1,242,420	1,135,934
Aptar Beauty
Financial information regarding the Company's reportable segments
Net Sales	302,859	323,980	951,666	979,956
Aptar Closures
Financial information regarding the Company's reportable segments
Net Sales	185,838	179,829	540,716	533,080
Operating segment
Financial information regarding the Company's reportable segments
Net Sales	917,032	901,452	2,762,563	2,678,225
Operating segment \| Aptar Pharma
Financial information regarding the Company's reportable segments
Net Sales	420,753	389,423	1,243,026	1,136,544
Adjusted EBITDA	151,594	136,344	425,260	371,508
Restructuring Initiatives	(564)	(92)	(653)	(1,657)
Operating segment \| Aptar Beauty
Financial information regarding the Company's reportable segments
Net Sales	308,955	330,467	972,535	1,002,209
Adjusted EBITDA	40,221	41,070	125,993	121,375
Restructuring Initiatives	(1,962)	(2,880)	(5,871)	(12,650)
Operating segment \| Aptar Closures
Financial information regarding the Company's reportable segments
Net Sales	187,324	181,562	547,002	539,472
Adjusted EBITDA	31,980	27,607	86,259	81,387
Restructuring Initiatives	(877)	(3,098)	(2,530)	(4,060)
Intersegment
Financial information regarding the Company's reportable segments
Net Sales	7,741	8,455	27,761	29,255
Intersegment \| Aptar Pharma
Financial information regarding the Company's reportable segments
Net Sales	159	235	606	610
Intersegment \| Aptar Beauty
Financial information regarding the Company's reportable segments
Net Sales	6,096	6,487	20,869	22,253
Intersegment \| Aptar Closures
Financial information regarding the Company's reportable segments
Net Sales	1,486	1,733	6,286	6,392
Corporate & Other, unallocated
Financial information regarding the Company's reportable segments
Adjusted EBITDA	(15,411)	(11,659)	(57,528)	(45,996)
Restructuring Initiatives	$ (461)	$ (91)	$ (605)	$ (1,261)

ACQUISITIONS (Details)

ACQUISITIONS (Details) - USD ($) $ in Thousands			9 Months Ended
ACQUISITIONS (Details) - USD ($) $ in Thousands	Aug. 01, 2023	Mar. 01, 2023	Sep. 30, 2024	Sep. 30, 2023
Acquisitions
Acquisition of businesses, net of cash acquired and release of escrow			$ 0	$ 16,570
Hengyu Acquisition
Acquisitions
Payments to acquire businesses	$ 5,200
iD SCENT
Acquisitions
Acquisition of businesses, net of cash acquired and release of escrow		$ 9,400
Cash acquired		1,400
Gulf Closures
Acquisitions
Acquisition of businesses, net of cash acquired and release of escrow		1,500
Cash acquired		$ 1,200
Percentage of interest acquired		80%
Valuation of full company equity of acquired company		$ 3,300
Non-controlling interest value		$ 700

INVESTMENT IN EQUITY SECURITI_3

INVESTMENT IN EQUITY SECURITIES - Schedule of Investments (Details) - USD ($) $ in Thousands	Sep. 30, 2024	Dec. 31, 2023
Schedule of Equity Method Investments [Line Items]
Total equity method investments and other investments	$ 51,052	$ 49,203
BTY
Schedule of Equity Method Investments [Line Items]
Equity Method Investments:	33,069	33,090
Sonmol
Schedule of Equity Method Investments [Line Items]
Equity Method Investments:	4,796	4,751
Desotec GmbH
Schedule of Equity Method Investments [Line Items]
Equity Method Investments:	1,000	905
PureCycle
Schedule of Equity Method Investments [Line Items]
Other Investments:	2,768	1,106
YAT
Schedule of Equity Method Investments [Line Items]
Other Investments:	5,414	5,352
Loop
Schedule of Equity Method Investments [Line Items]
Other Investments:	2,894	2,894
Others
Schedule of Equity Method Investments [Line Items]
Other Investments:	$ 1,111	$ 1,105

INVESTMENT IN EQUITY SECURITI_4

INVESTMENT IN EQUITY SECURITIES - Narrative (Details) € in Thousands						9 Months Ended		12 Months Ended	60 Months Ended
	Oct. 22, 2024 USD ($)	Apr. 26, 2024 USD ($)	Jul. 07, 2021 USD ($)	Apr. 01, 2020 USD ($)	Jan. 01, 2020 USD ($) company	Sep. 30, 2024 USD ($)	Sep. 30, 2023 USD ($)	Dec. 31, 2009 EUR (€)	Dec. 31, 2023 USD ($)	Mar. 31, 2021
Schedule of Equity Method Investments [Line Items]
Investment impairment						$ 0	$ 0
Goldrain \| Subsequent Event
Schedule of Equity Method Investments [Line Items]
Ownership percentage of equity method investment	40%
Investment in equity securities	$ 99,000,000
BTY
Schedule of Equity Method Investments [Line Items]
Ownership percentage of equity method investment					49%
Investment in equity securities					$ 32,000,000
Number of related companies \| company					3
Initial lock-up period (in years)					5 years
Second lock-up period (in years)					3 years
Purchases from related party						8,700,000	$ 10,700,000
Accounts payable and other accrued liabilities						$ 2,000,000			$ 1,800,000
BTY \| Call Option \| Minimum
Schedule of Equity Method Investments [Line Items]
Ownership percentage of equity method investment					26%
BTY \| Call Option \| Maximum
Schedule of Equity Method Investments [Line Items]
Ownership percentage of equity method investment					31%
Sonmol
Schedule of Equity Method Investments [Line Items]
Ownership percentage of equity method investment				30%
Investment in equity securities				$ 5,000,000
Desotec GmbH
Schedule of Equity Method Investments [Line Items]
Ownership percentage of equity method investment								23%
Investment in equity securities \| €								€ 574
Loop \| Preferred stock
Schedule of Equity Method Investments [Line Items]
Investment in equity securities									2,900,000
PureCycle
Schedule of Equity Method Investments [Line Items]
Investment ownership percentage										0.01
PureCycle \| Preferred stock
Schedule of Equity Method Investments [Line Items]
Investment in equity securities									3,000,000
Equity received in exchange for services		$ 200,000							$ 700,000
YAT
Schedule of Equity Method Investments [Line Items]
Investment in equity securities			$ 5,900,000
Investment ownership percentage			0.10

INVESTMENT IN EQUITY SECURITI_5

INVESTMENT IN EQUITY SECURITIES - Purecycle Investment (Details) - USD ($) $ in Thousands	9 Months Ended		12 Months Ended
	Sep. 30, 2024	Sep. 30, 2023	Dec. 31, 2023	Dec. 31, 2022	Dec. 31, 2021
Schedule of Equity Method Investments [Line Items]
Proceeds	$ 0	$ 5,604
PureCycle \| Preferred stock
Schedule of Equity Method Investments [Line Items]
Shares Sold (in shares)			510,449	157,600	191,349
Proceeds			$ 5,604	$ 1,599	$ 2,434
Realized Gain			$ 4,188	$ 1,213	$ 2,000

INVESTMENT IN EQUITY SECURITI_6

INVESTMENT IN EQUITY SECURITIES - Net Investment Gain/Loss (Details) - USD ($) $ in Thousands	3 Months Ended		9 Months Ended
	Sep. 30, 2024	Sep. 30, 2023	Sep. 30, 2024	Sep. 30, 2023
Schedule of Equity Method Investments [Line Items]
Net investment gain (loss)	$ 1,043	$ (1,240)	$ 1,495	$ 1,839
PureCycle \| Preferred stock
Schedule of Equity Method Investments [Line Items]
Net investment gain (loss)	$ 1,043	$ (1,240)	$ 1,495	$ 1,839

RESTRUCTURING INITIATIVES - Nar

RESTRUCTURING INITIATIVES - Narrative (Details) - USD ($) $ in Thousands	3 Months Ended		9 Months Ended
	Sep. 30, 2024	Sep. 30, 2023	Sep. 30, 2024	Sep. 30, 2023
Restructuring Cost and Reserve [Line Items]
Restructuring initiatives	$ 3,864	$ 6,161	$ 9,659	$ 19,628
Curtailment gain related to restructuring initiatives	1,851	0	1,851	0
Optimization Plan
Restructuring Cost and Reserve [Line Items]
Restructuring initiatives	3,900	$ 6,600	9,676	$ 20,100
Cumulative expense incurred	$ 61,300		$ 61,300

RESTRUCTURING INITIATIVES - Act

RESTRUCTURING INITIATIVES - Activity associated with optimization initiative (Details) - USD ($) $ in Thousands	3 Months Ended		9 Months Ended
	Sep. 30, 2024	Sep. 30, 2023	Sep. 30, 2024	Sep. 30, 2023
Restructuring reserve
Net Charges	$ 3,864	$ 6,161	$ 9,659	$ 19,628
Optimization Plan
Restructuring reserve
Beginning Reserve			29,888
Net Charges	3,900	$ 6,600	9,676	$ 20,100
Cash Paid			(18,881)
Interest and FX Impact			74
Ending Reserve	20,757		20,757
Employee severance \| Optimization Plan
Restructuring reserve
Beginning Reserve			27,078
Net Charges			6,003
Cash Paid			(15,321)
Interest and FX Impact			38
Ending Reserve	17,798		17,798
Professional fees and other costs \| Optimization Plan
Restructuring reserve
Beginning Reserve			2,810
Net Charges			3,673
Cash Paid			(3,560)
Interest and FX Impact			36
Ending Reserve	$ 2,959		$ 2,959